CN115160319B - 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 - Google Patents
含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 Download PDFInfo
- Publication number
- CN115160319B CN115160319B CN202110357313.2A CN202110357313A CN115160319B CN 115160319 B CN115160319 B CN 115160319B CN 202110357313 A CN202110357313 A CN 202110357313A CN 115160319 B CN115160319 B CN 115160319B
- Authority
- CN
- China
- Prior art keywords
- arh
- compound
- mmol
- nch
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 304
- 238000002360 preparation method Methods 0.000 title abstract description 13
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 title abstract description 8
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims abstract description 18
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims abstract description 18
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 229940114124 ferulic acid Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- 235000001785 ferulic acid Nutrition 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 2
- 102000042838 JAK family Human genes 0.000 claims 1
- 108091082332 JAK family Proteins 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- -1 t-butoxycarbonyl (Boc) protecting group Chemical group 0.000 description 288
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 199
- 101150065749 Churc1 gene Proteins 0.000 description 199
- 102100038239 Protein Churchill Human genes 0.000 description 199
- 230000015572 biosynthetic process Effects 0.000 description 163
- 238000003786 synthesis reaction Methods 0.000 description 162
- 125000005605 benzo group Chemical group 0.000 description 158
- 239000007787 solid Substances 0.000 description 134
- 238000000034 method Methods 0.000 description 120
- 238000005160 1H NMR spectroscopy Methods 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 239000007858 starting material Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 34
- 238000000746 purification Methods 0.000 description 34
- KQMXPHISFRKBJP-UHFFFAOYSA-N 1,3-benzodioxol-4-amine Chemical compound NC1=CC=CC2=C1OCO2 KQMXPHISFRKBJP-UHFFFAOYSA-N 0.000 description 33
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 30
- YQXAEBHPCJZKKX-SECBINFHSA-N tert-butyl (3r)-3-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1N1C2=NC=NC(N)=C2C(I)=N1 YQXAEBHPCJZKKX-SECBINFHSA-N 0.000 description 28
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 19
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 19
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 18
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 6
- 108010024121 Janus Kinases Proteins 0.000 description 5
- 102000015617 Janus Kinases Human genes 0.000 description 5
- 239000004012 Tofacitinib Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 229960001350 tofacitinib Drugs 0.000 description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 5
- HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 4
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FVOFFERFHBRNPL-SNVBAGLBSA-N tert-butyl (3r)-3-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1N1C2=NC=NC(N)=C2C(I)=C1 FVOFFERFHBRNPL-SNVBAGLBSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229960001507 ibrutinib Drugs 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- SWBLLSQMOMPTMC-UHFFFAOYSA-N naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 SWBLLSQMOMPTMC-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- TXWFUOLIFZLUBH-VIFPVBQESA-N tert-butyl (2s)-2-[(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CN1C2=NC=NC(N)=C2C(I)=N1 TXWFUOLIFZLUBH-VIFPVBQESA-N 0.000 description 3
- YQXAEBHPCJZKKX-UHFFFAOYSA-N tert-butyl 3-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1N1C2=NC=NC(N)=C2C(I)=N1 YQXAEBHPCJZKKX-UHFFFAOYSA-N 0.000 description 3
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- NGOTYFZFWPHNSU-UHFFFAOYSA-N 1,3-dioxol-4-amine Chemical compound NC1=COCO1 NGOTYFZFWPHNSU-UHFFFAOYSA-N 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- HALATUFUWLWCQV-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=CC(C(O)=O)=C1 HALATUFUWLWCQV-UHFFFAOYSA-N 0.000 description 2
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- KLKWCKQHBCUTCL-UHFFFAOYSA-N 5-iodo-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C(I)=CN2 KLKWCKQHBCUTCL-UHFFFAOYSA-N 0.000 description 2
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 2
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 102000042834 TEC family Human genes 0.000 description 2
- 108091082333 TEC family Proteins 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical group [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- UIJXHKXIOCDSEB-MRVPVSSYSA-N tert-butyl (3r)-3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](O)C1 UIJXHKXIOCDSEB-MRVPVSSYSA-N 0.000 description 2
- UIJXHKXIOCDSEB-QMMMGPOBSA-N tert-butyl (3s)-3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](O)C1 UIJXHKXIOCDSEB-QMMMGPOBSA-N 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
- FTNJQNQLEGKTGD-ZFJHNFROSA-N 1,3-benzodioxole Chemical group C1O[13C]=2[13CH]=[13CH][13CH]=[13CH][13C]=2O1 FTNJQNQLEGKTGD-ZFJHNFROSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AQFXIWDRLHRFIC-UHFFFAOYSA-N 1-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C(F)(F)F)C=C1C1=CC=CC=C1 AQFXIWDRLHRFIC-UHFFFAOYSA-N 0.000 description 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- XNDZRGTVUVVHQT-UHFFFAOYSA-N 3,4-dimethoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1OC XNDZRGTVUVVHQT-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- XAELQWGFCUUJNM-UHFFFAOYSA-N 3-chloro-1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2C(Cl)=C(C(=O)N)SC2=C1 XAELQWGFCUUJNM-UHFFFAOYSA-N 0.000 description 1
- HJTMIYKPPPYDRJ-UHFFFAOYSA-N 3-chloro-1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2C(Cl)=C(C(=O)O)SC2=C1 HJTMIYKPPPYDRJ-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- WMZNGTSLFSJHMZ-UHFFFAOYSA-N 3-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=CC(C(O)=O)=C1 WMZNGTSLFSJHMZ-UHFFFAOYSA-N 0.000 description 1
- LNYTUARMNSFFBE-UHFFFAOYSA-N 4-(diethylazaniumyl)benzoate Chemical compound CCN(CC)C1=CC=C(C(O)=O)C=C1 LNYTUARMNSFFBE-UHFFFAOYSA-N 0.000 description 1
- WEJHBEDHLLBJFW-UHFFFAOYSA-N 4-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1 WEJHBEDHLLBJFW-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- SIVYRLBDAPKADZ-UHFFFAOYSA-N 4-methylnaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C)=CC=C(C(O)=O)C2=C1 SIVYRLBDAPKADZ-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- KDVYCTOWXSLNNI-UHFFFAOYSA-N 4-t-Butylbenzoic acid Chemical compound CC(C)(C)C1=CC=C(C(O)=O)C=C1 KDVYCTOWXSLNNI-UHFFFAOYSA-N 0.000 description 1
- GRWXJRHEMNQLLE-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalene-1-carboxamide Chemical compound C1CCCC2=C1C=CC=C2C(=O)N GRWXJRHEMNQLLE-UHFFFAOYSA-N 0.000 description 1
- GCFQXKYHWFWGSB-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalene-1-carboxylic acid Chemical compound C1CCCC2=C1C=CC=C2C(=O)O GCFQXKYHWFWGSB-UHFFFAOYSA-N 0.000 description 1
- RCOVDZISUHLGQJ-UHFFFAOYSA-N 5-fluoro-1-benzofuran-2-carboxamide Chemical compound FC1=CC=C2OC(C(=O)N)=CC2=C1 RCOVDZISUHLGQJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004156 Azodicarbonamide Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019399 azodicarbonamide Nutrition 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- VIPHVHVAGBKHGR-UHFFFAOYSA-N hydron;pyridine-2-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CC=N1 VIPHVHVAGBKHGR-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- MNDFXDXRMYURMC-UHFFFAOYSA-N methyl 3-carbamoylbenzoate Chemical compound COC(=O)C1=CC=CC(C(N)=O)=C1 MNDFXDXRMYURMC-UHFFFAOYSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 1
- RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 1
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 1
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940018036 ritlecitinib Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
本发明公开了含1,3‑苯并二氧戊环结构的化合物及其制备方法与用途。本发明公开了一种通式(I)所示的1,3‑苯并二氧戊环衍生物，药理实验结果显示，本发明的化合物(I)可以对BTK和JAK3激酶产生良好的抑制作用，可用于制备治疗BTK、JAK3通路过度活化所致的类风湿性关节炎的药物；本发明还公开了所述1,3‑苯并二氧戊环衍生物的制备方法。
Description
技术领域
本发明属于药物化学领域，具体涉及一类含有1,3-苯并二氧戊环结构的BTK和JAK3激酶抑制剂，它们的制备方法，以及含有这些化合物的药物组合物及其在制备治疗类风湿性关节炎或B细胞淋巴瘤等自身免疫性疾病或B细胞恶性肿瘤等药物方面的用途。
技术背景
类风湿性关节炎(RA)是一种病因未明的慢性、以炎性滑膜炎为主的自身免疫性疾病，其主要病理表现为滑膜组织炎性细胞浸润、血管翳形成以及进行性关节软骨和骨破坏，最终导致关节畸形甚至功能丧失。
JAK(Janus Kinase)属于非受体酪氨酸激酶，包含四个亚型JAK1、JAK2、JAK3、TYK2。目前已有多种JAK抑制剂上市，如托法替尼(Tofacitinib)、鲁索替尼(Ruxolitinib)和巴瑞克替尼(Baricitinib)。托法替尼于2012年上市用于治疗中度至重度类风湿性关节炎，2017年又被批准用于治疗银屑病性关节炎。但托法替尼具有较严重的感染和贫血等副作用，究其原因，主要是由于托法替尼属于泛JAK抑制剂，在抑制JAK1和JAK3产生治疗效果的同时，由于抑制了JAK2活性而产生贫血的副作用。所以在治疗类风湿性关节炎时，应开发选择性JAK1或JAK3抑制剂。由于JAK1除了可与JAK3形成二聚体外，还可与JAK2或TYK2形成二聚体或多聚体，从而引起副作用。因此选择性抑制JAK3引起的副作用可能要小于抑制JAK1产生的副作用。
BTK(Bruton’s tyrosine kinase)是TEC家族的一员，属于非受体酪氨酸激酶，主要在B细胞、髓细胞、肥大细胞、血小板中表达，在T细胞和NK细胞中不表达。BTK在BCR信号通路中起到了至关重要的作用，除此之外，BTK还参与很多其他信号通路的传导。B细胞的异常活化会导致B细胞淋巴瘤和自身免疫性疾病。目前已有三个BTK抑制剂上市，包括依鲁替尼(Ibrutinib)、阿卡替尼(Acalabrutinib)和泽布替尼(Zanubrutinib)。
有文献报道联合使用BTK抑制剂LFM-A13和JAK3抑制剂JANEX-1治疗移植物抗宿主反应(GVHD)的效果要远优于单独使用LFM-A13、JANEX-1或甲氨蝶呤的治疗效果。另外JAK3选择性抑制剂PF-06651600在临床上显示出较好的抗RA效果，究其原因，不仅与抑制JAK3有关，也与抑制BTK等TEC家族激酶密切相关。因此我们认为同时抑制BTK和JAK3对治疗RA等自身免疫性疾病具有协同增效作用。
发明内容
发明目的：本发明公开了一类含有1,3-苯并二氧戊环结构的化合物，并提供了该类化合物的具体制备方法以及作为BTK和JAK3激酶抑制剂的制药应用。
技术方案：本发明公开了一类如通式(I)所示的1,3-苯并二氧戊环衍生物或其药学上可接受的盐：
其中：X代表N或CH；A代表O、S、-NHCO-、-NHCOCH2-或-NHSO2-；m代表0或1，n代表0或1；
R1代表： 其中p代表0或1；R4代表H、F、Cl、Br、I、C1-C6烷基、CF3、OH、C1-C6烷氧基、OCF3、CN、NO2、NH2、C1-C6的烷胺基、N(CH3)2、N(C2H5)2、NHCOCH3、CONH2、CONHCH3、CONHCH2CF3、OCH2CH2OCH3、C6H5、/>R4可以是单取代、双取代或三取代；Y1、Y2、Y3或Y4代表N或C-R5，R5代表H、F、Cl、Br、I、CH3、CF3、OH、OCH3、OCF3或CN；Z代表O、S或N-R6，R6代表H、CH3或C2H5或环丙基；
R2代表H、Cl、Br或CN；
R3代表H、取代的C1-C6的烷基、取代的C2-C6的杂环烷基，取代基为OH、NH2、OCH3、NHCH3或NHCOCH3，所述杂环烷基为含有1～3个O、N或S原子的四元、五元或六元饱和杂环。
其中：A优选-NHCO-或-NHSO2-。A更优选-NHCO-。
当m代表1时，n优选代表0。
当m代表0时，n优选代表1。
R2、R3优选代表H。
本发明的化合物优选如下通式(II)：
其中：X和R1的定义同前。
R1优选代表 其中R7代表H、F、Cl、Br、CH3、t-Bu、CF3、CN、OH、OCH3、OCF3、NH2、N(CH3)2、N(C2H5)2、NHCOCH3、CONH2、CONHCH3、CONHCH2CF3、C6H5、/>R7可以是单取代、双取代或三取代，R8代表H、Cl或CH3。
R7优选代表H、Cl、CH3、t-Bu、CF3、OCH3、N(CH3)2、N(C2H5)2或CONHCH2CF3，R7可以是单取代、双取代或三取代，R8优选代表Cl。
更优选地，本发明所述1,3-苯并二氧戊环衍生物选自以下化合物：
上述化合物的药学上可接受的盐为通式(I)化合物的酸加成盐，其中用于成盐的酸为：氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
本发明通式(I)的化合物可用下列方法制备：
其中，R1、R2、R3、X、A、m和n的定义同前；
由化合物(III)与化合物(IV)通过Suzuki偶联反应制备化合物(V)，所用溶剂选自甲苯、N,N-二甲基甲酰胺(DMF)、乙二醇二甲醚、1,4-二氧六环、四氢呋喃、甲醇、乙醇、乙腈、丙酮、水或任意两种溶剂组成的混合溶剂，优选乙二醇二甲醚；所用碱选自乙醇钠、乙酸钠、乙酸钾、磷酸钾、氢氧化钠、氢氧化钾、碳酸钾、碳酸钠或三乙胺，优选碳酸钠或碳酸钾；所用催化剂选自四(三苯基膦)钯(Pd(PPh3)4)、[1,1'-双(二苯基膦基)二茂铁]二氯化钯(Pd(dppf)Cl2)、双(三苯基磷)二氯化钯(Pd(PPh3)2Cl2)、醋酸钯(Pd(OAc)2)或(1,1'-双(二苯基膦)二茂铁)二氯化镍(NiCl2(dppf))，优选Pd(dppf)Cl2；反应温度选自室温至120℃，优选70～100℃。
由化合物(V)通过脱除叔丁氧羰基(Boc)保护基制备化合物(VI)，所用试剂选自三氟乙酸、浓盐酸、氯化氢/乙酸乙酯溶液或氯化氢/甲醇溶液,优选三氟乙酸或氯化氢/乙酸乙酯溶液；反应溶剂选自丙酮、二氯甲烷、乙酸乙酯、1,4-二氧六环或乙腈,优选乙酸乙酯或二氯甲烷。
由化合物(VI)与相应的酰氯反应制备化合物(I)，所用缚酸剂选自三乙胺、吡啶、N,N-二异丙基乙胺、4-二甲氨基吡啶、碳酸钾或碳酸钠，优选三乙胺；所用溶剂选自二氯甲烷、四氢呋喃、1,4-二氧六环、乙酸乙酯、丙酮、甲苯或DMF，优选二氯甲烷。
化合物(I)也可由化合物(VI)与相应的酸在缩合剂存在下反应制备得到，所述缩合剂选自N,N'-羰基二咪唑(CDI)、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDCI)/1-羟基苯并三唑(HOBt)或二环己基碳二亚胺(DCC)/4-二甲氨基吡啶(DMAP)，优选EDCI/HOBt。
当A代表-NHCO-、m代表0、n代表1、R2、R3代表H，且哌啶3位C原子为R构型时，本发明通式(II)的化合物可用下列方法制备：
其中，R1和X的定义同前；
由化合物(III-A)与化合物(IV-A)通过Suzuki偶联反应制备化合物(V-A)，所用溶剂选自甲苯、DMF、乙二醇二甲醚、1,4-二氧六环、四氢呋喃、甲醇、乙醇、乙腈、丙酮、水或任意两种溶剂组成的混合溶剂，优选乙二醇二甲醚；所用的碱选自乙醇钠、乙酸钠、乙酸钾、磷酸钾、氢氧化钠、氢氧化钾、碳酸氢钾、碳酸钾、碳酸钠或三乙胺，优选碳酸钠或碳酸钾；所用的催化剂选自Pd(PPh3)4、Pd(dppf)Cl2、Pd(PPh3)2Cl2、Pd(OAc)2或NiCl2(dppf)，优选Pd(dppf)Cl2；反应温度选自25～120℃，优选70～100℃；反应时间选自2～24小时，优选12～18小时。
由化合物(V-A)通过脱除Boc保护基制备化合物(VI-A)，所用试剂选自三氟乙酸、浓盐酸、氯化氢/乙酸乙酯溶液或氯化氢/甲醇溶液,优选氯化氢/乙酸乙酯溶液；反应溶剂选自丙酮、二氯甲烷、乙酸乙酯、1,4-二氧六环或乙腈,优选乙酸乙酯或二氯甲烷。
由化合物(VI-A)与丙烯酰氯反应制备化合物(II)，所用缚酸剂选自三乙胺、吡啶、N,N-二异丙基乙胺、4-二甲氨基吡啶、碳酸钾或碳酸钠，优选三乙胺；所用溶剂选自二氯甲烷、四氢呋喃、丙酮、甲苯或DMF，优选二氯甲烷。
化合物(II)也可由化合物(VI-A)与丙烯酸在缩合剂存在下反应制得，所述缩合剂选自CDI、EDCI/HOBt或DCC/DMAP，优选EDCI/HOBt。
中间体(III)可用下列方法制备：
其中，X、m和n的定义同前；
由化合物(VII)与化合物(VIII)通过Mitsunobu反应制备化合物(III)，所用膦配体选自三苯基膦(PPh3)或三正丁基膦(n-Bu3P)；所用偶氮试剂选自偶氮二碳酸二乙酯(DEAD)、偶氮二碳酸二异丙酯(DIAD)或N,N,N',N'-四甲基偶氮二甲酰胺(TMAD)；所用溶剂选自四氢呋喃、1,4-二氧六环、乙醚、二氯甲烷、甲苯、乙腈或DMF。
中间体(IV)可用下列方法制备：
其中，A选自-NHCO-、-NHCOCH2-或-NHSO2-，R1的定义同前；
苯并[d][1,3]二氧杂环戊烯-4-胺(IX)溶于DMF，加入N-溴代丁二酰亚胺(NBS)进行溴代即得7-溴苯并[d][1,3]二氧杂环戊烯-4-胺(X)。
化合物(X)和联硼酸频那醇酯溶于1,4-二氧六环中，在催化剂Pd(dppf)Cl2和乙酸钾存在下反应即得7-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-胺(XI)。
由化合物(XI)与相应的酰氯反应制备中间体(IV)，所用缚酸剂选自三乙胺、吡啶、N,N-二异丙基乙胺、4-二甲氨基吡啶、碳酸钾或碳酸钠，优选N,N-二异丙基乙胺或三乙胺；所用溶剂选自二氯甲烷、四氢呋喃、1,4-二氧六环、乙酸乙酯、丙酮、甲苯或DMF，优选二氯甲烷。
本发明还公开了一种药物组合物，其含有上述通式(I)化合物或其药学上可接受的盐及药学上可接受的载体。所述的化合物可以添加药学上可接受的载体制成常见的药用制剂，如片剂、胶囊、糖浆、悬浮剂、注射剂，可以加入香料、甜味剂、液体或固体填料或稀释剂等常用药用辅料。
本发明所述的通式(I)化合物及其立体异构体、水合物、溶剂合物或结晶在制备BTK和JAK3抑制剂药物中的应用也在本发明的保护范围内。
进一步地，其中的BTK和JAK3抑制剂用于制备治疗自身免疫性疾病和B细胞恶性肿瘤的药物，所述的自身免疫性疾病包括类风湿性关节炎、银屑病和斑秃等，所述的B细胞恶性肿瘤包括B细胞淋巴瘤等。
有益效果：本发明公开了一种通式(I)所示的1,3-苯并二氧戊环衍生物，药理实验结果显示，本发明的化合物(I)可以对BTK和JAK3激酶产生良好的抑制作用，可用于制备治疗BTK、JAK3通路过度活化所致的类风湿性关节炎的药物；本发明还公开了所述1,3-苯并二氧戊环衍生物的制备方法。
具体实施方式
下面结合具体实施例对本申请作出详细说明。
实施例1
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅰ-1)的合成(R)-3-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅲ-1)的合成
将4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶(Ⅶ-1)(1.80g,6.90mmol)、(S)-1-叔丁氧羰基-3-羟基哌啶(Ⅷ-1)(2.78g,13.79mmol)、PPh3(3.61g,13.79mmol)、无水THF(100mL)加入250mL三颈瓶中，氮气保护，冰浴下搅拌30分钟，加入DIAD(2.40g,13.79mmol)，室温反应18小时。减压蒸除THF，加乙酸乙酯(100mL)溶解，依次用饱和碳酸钠(30mL×3)、水(30mL×3)、饱和氯化钠(30mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压蒸除溶剂得黄色油状物，柱层析分离(洗脱剂:二氯甲烷:甲醇＝150～90:1)，得白色固体2.06g，产率67.2％，m.p.178-180℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.34(s,1H,ArH),6.27(s,2H,NH2),4.85-4.66(m,1H,CHCH 2N),4.36-4.00(m,2H,CHCH 2N),3.47-3.21(m,1H,CHCH2CH2CH 2N),2.92-2.72(m,1H,CHCH2CH2CH 2N),2.28-2.01(m,2H,CHCH 2CH2CH2N),1.97-1.79(m,1H,CHCH2CH 2CH2N),1.76-1.57(m,1H,CHCH2CH 2CH2N),1.45(s,9H,NBoc)。
7-溴苯并[d][1,3]二氧杂环戊烯-4-胺(X)的合成
将苯并[d][1,3]二氧杂环戊烯-4-胺(Ⅸ)(1.24g,9.04mmol)和DMF(30mL)混合，搅拌溶解，降温至-30℃，分批加入NBS(1.69g,9.50mmol)，加毕，保温反应1小时。加入水(60mL)，用乙酸乙酯(15mL×3)萃取，有机相依次用水(10mL×3)和饱和氯化钠溶液(10mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压蒸干，残留物柱层析(洗脱剂:石油醚:乙酸乙酯＝30～10:1)分离，得白色固体1.01g，收率为51.7％，m.p.99-100℃。1H-NMR(300MHz,CDCl3)δ(ppm):6.80(d,J＝8.67Hz,1H,ArH),6.23(d,J＝8.67Hz,1H,ArH),6.02(s,2H,OCH2O),3.58(s,2H,NH2)。
7-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-胺(XI)的合成
将化合物Ⅹ(3.14g,14.54mmol)、联硼酸频那醇酯(7.39g,29.07mmol)、Pd(dppf)Cl2(0.53g,0.73mmol)、乙酸钾(4.28g,43.62mmol)和1,4-二氧六环(25mL)混合，N2保护，升温至95℃反应12小时。经硅藻土抽滤，滤液减压蒸除溶剂，加入乙酸乙酯(20mL)溶解，依次用水(10mL×3)和饱和氯化钠溶液(10mL×3)洗涤，无水硫酸钠干燥，抽滤，滤液减压蒸干，残留物柱层析(洗脱剂:石油醚:二氯甲烷＝1:5～10)得白色固体2.70g，收率70.6％，mp.84-86℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.09(d,J＝8.16Hz,1H,ArH),6.31(d,J＝8.19Hz,1H,ArH),5.99(s,2H,OCH2O),3.71(br,2H,NH2),1.34(s,12H,4CH3)。
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-1)的合成
将化合物Ⅺ(0.56g,2.14mmol)溶于二氯甲烷(10mL)中，加入N,N-二异丙基乙胺(0.83g,6.42mmol)，冰浴下滴加苯甲酰氯(0.45g,3.21mmol)的二氯甲烷溶液，滴毕，室温反应0.5小时。反应液依次用1mol/L盐酸(10mL×3)、饱和碳酸氢钠溶液(10mL×3)、水(10mL×3)和饱和氯化钠溶液(10mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压蒸干，残留物柱层析(洗脱剂:石油醚:二氯甲烷＝1:1～8)得白色固体409mg，收率为52.1％，m.p.202-204℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.89-7.88(m,4H,ArH),7.57-7.47(m,3H,ArH,NH),7.29(d,J＝8.73Hz,1H,ArH),6.07(s,2H,OCH2O),1.36(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-苯甲酰胺基苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(V-1)的合成
将化合物Ⅲ-1(1.50g,3.38mmol)和Ⅳ-1(1.49g,4.05mmol)加入100mL单颈瓶中，加入2mol/L碳酸钠溶液(3.38mL)、Pd(dppf)Cl2(0.12g,0.17mmol)和乙二醇二甲醚(40mL)，氮气保护，85℃反应17小时。冷至室温，经硅藻土抽滤，滤液减压浓缩，乙酸乙酯(40mL)溶解，水(10mL×3)洗涤，饱和氯化钠(10mL×3)洗涤，减压浓缩得2.56g粗品。柱层析(洗脱剂:二氯甲烷:甲醇＝100～70:1)分离得926mg淡黄色固体，产率49.2％，m.p.112-114℃。1H-NMR(300MHz,CDCl3+D2O)δ(ppm):8.36(s,1H,ArH),8.05-7.98(m,1H,ArH),7.92(d,J＝7.23Hz,2H,ArH),7.64-7.49(m,3H,ArH),7.15(d,J＝8.19Hz,1H,ArH),6.13(s,2H,OCH2O),4.92-4.79(m,1H,CHCH 2NBoc),4.42-4.23(m,1H,CHCH2NBoc),3.57-3.28(m,2H,CH 2NCH 2),2.92-2.76(m,1H,NCH 2CH2),2.32-2.16(m,2H,NCH2CHCH 2),1.93-1.81(m,2H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅵ-1)的合成
将化合物Ⅴ-1(0.93g,1.66mmol)溶于乙酸乙酯(6mL)中，加入乙酸乙酯的氯化氢饱和溶液(10mL)，室温搅拌4小时，有大量固体析出。加入20mL水，分液，水层用乙酸乙酯洗涤两次，用1mol/L的NaOH调pH至8-9，析出固体，抽滤，烘干得721mg淡黄色固体，产率94.8％。不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅰ-1)的合成
将化合物Ⅵ-1(93mg,0.20mmol)溶于5mL无水二氯甲烷中，加入三乙胺(31mg,0.30mmol)，冰浴下滴加丙烯酰氯(22mg,0.24mmol)的无水二氯甲烷溶液，滴加完毕，室温搅拌3.5小时。水(10mL×3)洗涤，饱和氯化钠溶液(10mL×3)洗涤，减压浓缩得粗品。残留物柱层析(洗脱剂:二氯甲烷:甲醇＝100～35:1)分离得77mg白色固体，产率74.0％，m.p.141-142.5℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.39(s,1H,ArH),8.35-8.25(m,1H,NH),7.93(d,J＝7.26Hz,2H,ArH),7.86-7.76(m,1H,ArH),7.60-7.44(m,3H,ArH),7.13-7.03(m,1H,ArH),6.67-6.52(m,1H,CH＝CH2),6.34-6.18(m,2H,CH＝CH2,NH2),6.09(s,2H,OCH2O),5.75-5.60(m,1H,CH＝CH2),4.93-4.74(m,1.5H,NCH 2CH),4.65-4.51(m,0.5H,NCH2CH),4.27-4.14(m,0.5H,NCH 2CH),4.08-3.94(m,0.5H,NCH 2CH),3.85-3.68(m,0.5H,NCH 2CH2),3.40-3.26(m,0.5H,NCH 2CH2),3.24-3.08(m,0.5H,NCH 2CH2),2.92-2.85(m,0.5H,NCH 2CH2),2.81(s,1H,NH2),2.46-2.30(m,1H,NCH2CHCH 2),2.29-2.18(m,1H,NCH2CHCH 2),2.06-1.91(m,1H,NCH2CH 2),1.79-1.61(m,1H,NCH2CH 2)。HRMS(ESI):m/z[M+H]+.Calcd for C27H26N7O4:512.2046；Found:512.2045.
实施例2
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)噻吩-2-甲酰胺(Ⅰ-2)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)噻吩-2-甲酰胺(Ⅳ-2)的合成
将噻吩-2-甲酸(0.73g,5.70mmol)溶于无水二氯甲烷(12mL)中，加入3滴DMF，冰浴下滴加草酰氯(1.09g,8.55mmol)的无水二氯甲烷溶液。滴毕，室温搅拌。TLC(石油醚:乙酸乙酯＝3:1)监测，原料反应完全后，减压除去溶剂，无水二氯甲烷(15mL)溶解，待用。
向50mL茄形瓶中加入化合物Ⅺ(1.00g,3.80mmol)和二氯甲烷(20mL)，搅拌溶解，加入N,N-二异丙基乙胺(1.47g,11.40mmol)，冰浴下滴加上述酰氯，室温反应6小时。有机相依次用1mol/L盐酸(10mL×3)、水(10mL)、饱和碳酸氢钠溶液(10mL)、饱和氯化钠溶液(10mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压浓缩得淡黄色固体。石油醚:乙酸乙酯8:1打浆(1g/6mL)，得白色固体1.25g，产率88.1％，不经进一步纯化，直接投下一步。
(R)-3-(4-氨基-3-(7-(噻吩-2-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-2)的合成
以化合物Ⅲ-1(0.90g,2.03mmol)和Ⅳ-2(0.91g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体583mg，产率51.1％，m.p.142-144℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.35(s,1H,ArH),7.94-7.87(m,2H,ArH,NH),7.69(d,J＝3.66Hz,1H,ArH),7.60(d,J＝5.01Hz,1H,ArH),7.20-7.08(m,2H,ArH),6.12(s,2H,OCH2O),5.93(br,2H,NH2),4.93-4.78(m,1H,CHCH 2NBoc),4.46-4.07(m,2H,CHCH 2NBoc),3.56-3.29(m,1H,NCH 2CH2),2.94-2.75(m,1H,NCH 2CH2),2.35-2.13(m,2H,NCH2CHCH 2),1.98-1.82(m,1H,NCH2CH 2),1.77-1.59(m,1H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-噻吩-2-甲酰胺(Ⅵ-2)的合成
以化合物Ⅴ-2(400mg,0.71mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体329mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)噻吩-2-甲酰胺(Ⅰ-2)的合成
以化合物Ⅵ-2(300mg,0.65mmol)和丙烯酰氯(64mg,0.71mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体131mg，产率39.1％，m.p.140-142℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.37(s,1H,ArH),8.02(s,1H,NH),7.89(d,J＝7.98Hz,1H,ArH),7.73(d,J＝3.27Hz,1H,ArH),7.62(d,J＝4.74Hz,1H,ArH),7.18(d,J＝3.60Hz,1H,ArH),7.12(d,J＝8.70Hz,1H,ArH),6.72-6.54(m,1H,CH＝CH2),6.39-6.25(m,1H,CH＝CH2),6.14(s,2H,OCH2O),5.96(s,1H,NH2),5.79-5.63(m,1H,CH＝CH2),4.99-4.82(m,1.5H,NCH 2CH),4.71-4.58(m,0.5H,NCH2CH),4.32-4.18(m,0.5H,NCH 2CH),4.12-3.99(m,0.5H,NCH 2CH),3.89-3.73(m,0.5H,NCH 2CH2),3.47-3.32(m,0.5H,NCH 2CH2),3.30-3.14(m,0.5H,NCH 2CH2),2.97-2.79(m,0.5H,NCH 2CH2),2.49-2.34(m,1H,NCH2CHCH 2),2.33-2.23(m,1H,NCH2CHCH 2),2.20(s,1H,NH2),2.07-1.96(m,1H,NCH2CH 2),1.83-1.67(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd forC25H24N7O4S:518.1610；Found:518.1611.
实施例3
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡咯-2-甲酰胺(Ⅰ-3)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡咯-甲酰胺(Ⅳ-3)的合成
以化合物Ⅺ(1.00g,3.80mmol)和吡咯-2-羧酸(0.63g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得白色固体1.17g，产率86.4％，不经进一步纯化，直接投下一步。
(R)-3-(3-(7-(1H-吡咯-2-甲酰胺)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-3)的合成
以化合物Ⅲ-1(0.90g,2.03mmol)和Ⅳ-3(1.36g,3.85mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体550mg，产率49.5％，m.p.138-140℃。1H-NMR(400MHz,CDCl3)δ(ppm):11.67(s,1H,NH),8.42(s,1H,ArH),7.77(d,J＝8.52Hz,1H,ArH),7.70(s,1H,NH),7.15-7.10(m,1H,ArH),7.08(d,J＝8.60Hz,1H,ArH),6.87-6.82(m,1H,ArH),6.38-6.31(m,1H,ArH),6.11(s,2H,OCH2O),5.30(s,1H,NH2),4.92-4.78(m,1H,CHCH 2NBoc),4.50-4.24(m,1H,CHCH2NBoc),4.24-4.03(m,1H,CHCH 2NBoc),3.58-3.29(m,1H,NCH 2CH2),2.91-2.75(m,1H,NCH 2CH2),2.36-2.16(m,3H,NCH2CHCH 2,NH2),1.96-1.82(m,1H,NCH2CH 2),1.78-1.63(m,1H,NCH2CH 2),1.45(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡咯-2-甲酰胺(Ⅵ-3)的合成
以化合物Ⅴ-3(450mg,0.82mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体383mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡咯-2-甲酰胺(Ⅰ-3)的合成
以化合物Ⅵ-3(360mg,0.81mmol)和丙烯酰氯(77mg,0.85mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体212mg，产率52.5％，m.p.156-158℃。1H-NMR(300MHz,CDCl3+D2O)δ(ppm):8.40(s,1H,ArH),7.80-7.60(m,1H,ArH),7.18-6.99(m,2H,ArH),6.94-6.81(m,1H,ArH),6.70-6.52(m,1H,CH＝CH2),6.43-6.22(m,2H,ArH,CH＝CH2),6.09(s,2H,OCH2O),5.80-5.60(m,1H,CH＝CH2),5.07-4.54(m,4H,NCH 2CH,NH 2),4.31-4.15(m,0.5H,NCH 2CH),4.10-3.93(m,0.5H,NCH 2CH),3.87-3.65(m,0.5H,NCH 2CH2),3.46-3.30(m,0.5H,NCH 2CH2),3.26-3.11(m,0.5H,NCH 2CH2),2.95-2.76(m,0.5H,NCH 2CH2),2.48-2.14(m,2H,NCH2CHCH 2),2.05-1.89(m,1H,NCH2CH 2),1.83-1.60(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd forC25H25N8O4:501.1999；Found:501.2003。
实施例4
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)吡啶-2-甲酰胺(Ⅰ-4)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)吡啶-2-甲酰胺(Ⅳ-4)的合成
以化合物Ⅺ(0.70g,2.66mmol)和吡啶-2-甲酰氯盐酸盐(0.57g,3.19mmol)为原料，操作过程同化合物Ⅳ-1，得灰白色固体612mg，产率62.5％，m.p.190-192℃。1H-NMR(300MHz,CDCl3)δ(ppm):10.11(s,1H,NH),8.70-8.66(m,1H,ArH),8.29(d,J＝7.65Hz,1H,ArH),8.00(d,J＝8.43Hz,1H,ArH),7.93(t,J＝7.56Hz,1H,ArH),7.54-7.44(m,1H,ArH),7.30(d,J＝8.55Hz,1H,ArH),6.11(s,2H,OCH2O),1.37(s,12H,4CH3).
(R)-3-(4-氨基-3-(7-(吡啶-2-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-4)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和化合物Ⅳ-4(0.80g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体476mg，产率47.4％，m.p.118-120℃。1H-NMR(300MHz,CDCl3)δ(ppm):10.17(s,1H,NH),8.70-8.66(m,1H,ArH),8.39(s,1H,ArH),8.33(d,J＝7.77Hz,1H,ArH),8.17(d,J＝8.70Hz,1H,ArH),7.96(td,J1＝7.74Hz,J2＝1.65Hz,1H,ArH),7.58-7.51(m,1H,ArH),7.18(d,J＝8.70Hz,1H,ArH),6.18(s,2H,OCH2O),5.79(s,2H,NH2),4.94-4.81(m,1H,CHCH 2NBoc),4.43-4.27(m,1H,CHCH2NBoc),4.23-4.10(m,1H,CHCH 2NBoc),3.52-3.39(m,1H,NCH 2CH2),2.94-2.79(m,1H,NCH 2CH2),2.34-2.27(m,1H,NCH2CHCH 2),2.26-2.20(m,1H,NCH2CHCH 2),1.98-1.90(m,2H,NCH2CH 2),1.47(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)吡啶-2-甲酰胺(Ⅵ-4)的合成
将化合物Ⅴ-4(0.40g,0.72mmol)溶于无水二氯甲烷(5mL)中，加入三氟醋酸(5mL)，室温搅拌10小时。减压蒸去溶剂，乙酸乙酯溶解，1mol/L NaOH调pH至8-9，分液，水层用乙酸乙酯萃取1次，有机层用饱和氯化钠(10mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压浓缩得280mg淡黄色产品，产率85.37％。不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)吡啶-2-甲酰胺(Ⅰ-4)的合成
将化合物Ⅵ-4(230mg,0.50mmol)、丙烯酸(43mg,0.60mmol)、HOBt(102mg,0.75mmol)、EDCI(145mg,0.75mmol)和TEA(102mg,1.00mmol)溶于6mL DMF中，室温搅拌12h。加入30mL水，乙酸乙酯(10mL×3)萃取，有机层依次用1mol/L盐酸(10mL×3)、饱和碳酸钠(10mL×3)和饱和氯化钠(10mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压浓缩得粗品。柱层析(洗脱剂:二氯甲烷:甲醇＝100～50:1)得白色固体201mg，产率78.2％，m.p.154-156℃。1H-NMR(300MHz,CDCl3)δ(ppm):10.11(s,1H,NHCO),8.61(s,1H,ArH),8.36-8.21(m,2H,ArH),8.16-8.03(m,1H,ArH),7.97-7.84(m,1H,ArH),7.55-7.40(m,1H,ArH),7.16-7.02(m,1H,ArH),6.64-6.46(m,1H,CH＝CH2),6.34-6.19(m,1H,CH＝CH2),6.12(s,2H,OCH2O),5.78(s,1H,NH2),5.68-5.57(m,1H,CH＝CH2),4.96-4.74(m,1.5H,NCH 2CH),4.65-4.52(m,0.5H,NCH2CH),4.24-4.12(m,0.5H,NCH 2CH),4.05-3.92(m,0.5H,NCH 2CH),3.80-3.67(m,0.5H,NCH 2CH2),3.42-3.26(m,0.5H,NCH 2CH2),3.20-3.07(m,0.5H,NCH 2CH2),2.90-2.73(m,0.5H,NCH 2CH2),2.44-2.15(m,2H,NCH2CHCH 2),2.04-1.84(m,3H,NCH2CH 2,NH2)；HRMS(ESI):m/z[M+H]+.Calcd for C26H25N8O4:513.1999；Found:513.1999。
实施例5
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-氯苯甲酰胺(Ⅰ-5)的合成
2-氯-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-5)的合成
以化合物Ⅺ(0.80g,3.04mmol)和邻氯苯甲酰氯(0.80g,4.56mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体800mg，产率65.5％，m.p.96-98℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.16(s,1H,NHCO),7.91(d,J＝8.37Hz,1H,ArH),7.81(d,J＝6.57Hz,1H,ArH),7.48-7.37(m,3H,ArH),7.31(d,J＝8.22Hz,1H,ArH),6.08(s,2H,OCH2O),1.39(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(2-氯苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-5)的合成
以化合物Ⅲ-1(0.65g,1.46mmol)和Ⅳ-5(0.71g,1.76mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体651mg，产率75.2％，m.p.124-126℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.36(s,1H,ArH),8.16(s,1H,NH),8.06(d,J＝8.58Hz,1H,ArH),7.86(d,J＝6.24Hz,1H,ArH),7.52-7.40(m,3H,ArH),7.15(d,J＝8.70Hz,1H,ArH),6.12(s,2H,OCH2O),5.75(s,2H,NH2),4.93-4.77(m,1H,CHCH 2NBoc),4.44-4.23(m,1H,CHCH2NBoc),4.22-4.04(m,1H,CHCH 2NBoc),3.54-3.35(m,1H,NCH 2CH2),2.91-2.76(m,1H,NCH 2CH2),2.32-2.18(m,2H,NCH2CHCH 2),1.78-1.61(m,2H,NCH2CH 2),1.45(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-氯苯甲酰胺(Ⅵ-5)的合成
以化合物Ⅴ-5(600mg,1.01mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体524mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-氯苯甲酰胺(Ⅰ-5)的合成
以化合物Ⅵ-5(450mg,0.91mmol)和丙烯酰氯(87mg,0.96mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体270mg，产率54.0％，m.p.156.5-158℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.39-8.27(m,2H,ArH,CONH),8.03(d,J＝8.61Hz,1H,ArH),7.83(d,J＝7.47Hz,1H,ArH),7.52-7.36(m,3H,ArH),7.13(d,J＝8.55Hz,1H,ArH),6.68-6.52(m,1H,CH＝CH2),6.34-6.22(m,1H,CH＝CH2),6.12(s,2H,OCH2O),6.04(s,1H,NH2),5.76-5.61(m,1H,CH＝CH2),4.95-4.79(m,1.5H,NCH 2CH),4.70-4.56(m,0.5H,NCH2CH),4.28-4.16(m,0.5H,NCH 2CH),4.09-3.96(m,0.5H,NCH 2CH),3.84-3.70(m,0.5H,NCH 2CH2),3.44-3.29(m,0.5H,NCH 2CH2),3.25-3.11(m,0.5H,NCH 2CH2),2.92-2.77(m,0.5H,NCH 2CH2),2.52-2.19(m,3H,NCH2CHCH 2,NH2),2.04-1.91(m,1H,NCH2CH 2),1.82-1.63(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C27H25ClN7O4:546.1657；Found:546.1656.
实施例6
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯甲酰胺(Ⅰ-6)的合成
3-氯-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-6)的合成
以化合物Ⅺ(0.80g,3.04mmol)和间氯苯甲酰氯(0.80g,4.56mmol)为原料，操作过程同化合物Ⅳ-1。得白色固体987mg，产率80.8％，m.p.150-152℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.88-7.86(m,1H,ArH),7.84-7.80(m,2H,ArH,NH),7.74(d,J＝7.68Hz,1H,ArH),7.53(d,J＝8.04Hz,1H,ArH),7.43(t,J＝7.80Hz,1H,ArH),7.28(d,J＝8.31Hz,1H,ArH),6.07(s,2H,OCH2O),1.36(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(3-氯苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-6)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-6(0.87g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体1.02g(粗品)，产率95.6％，m.p.128-130℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.35(s,1H,ArH),8.03(s,1H,NH),7.95-7.85(m,2H,ArH),7.79(d,J＝7.29Hz,1H,ArH),7.55(d,J＝7.98Hz,1H,ArH),7.44(t,J＝7.71Hz,1H,ArH),7.13(d,J＝8.58Hz,1H,ArH),6.12(s,2H,OCH2O),5.89(s,2H,NH2),4.93-4.75(m,1H,CHCH 2NBoc),4.47-4.22(m,1H,CHCH2NBoc),4.21-4.02(m,1H,CHCH 2NBoc),3.56-3.29(m,1H,NCH 2CH2),2.93-2.75(m,1H,NCH 2CH2),2.36-2.19(m,2H,NCH2CHCH 2),1.97-1.79(m,1H,NCH2CH 2),1.77-1.60(m,1H,NCH2CH 2),1.45(s,9H,Boc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯甲酰胺(Ⅵ-6)的合成
以化合物Ⅴ-6(1.00g,1.69mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体882mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯甲酰胺(Ⅰ-6)的合成
以化合物Ⅵ-6(500mg,1.02mmol)和丙烯酰氯(97mg,1.07mmol)为原料，操作过程同化合物Ⅰ-1，得372mg白色固体，产率67.0％，m.p.143-144.5℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.34(d,J＝11.04Hz,1H,ArH),8.21(d,J＝9.12Hz,1H,ArH),7.92(s,1H,NH),7.90-7.77(m,2H,ArH),7.55(d,J＝7.77Hz,1H,ArH),7.45(t,J＝7.65Hz,1H,ArH),7.16-7.05(m,1H,ArH),6.68-6.52(m,1H,CH＝CH2),6.34-6.22(m,1H,CH＝CH2),6.12(s,2H,OCH2O),6.02(s,1H,NH2),5.76-5.61(m,1H,CH＝CH2),4.95-4.78(m,1.5H,NCH 2CH),4.68-4.55(m,0.5H,NCH2CH),4.28-4.16(m,0.5H,NCH 2CH),4.10-3.97(m,0.5H,NCH 2CH),3.85-3.69(m,0.5H,NCH 2CH2),3.45-3.29(m,0.5H,NCH 2CH2),3.26-3.11(m,0.5H,NCH 2CH2),2.93-2.79(m,0.5H,NCH 2CH2),2.49-2.18(m,3H,NCH2CHCH 2,NH2),2.07-1.91(m,1H,NCH2CH 2),1.81-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C27H25ClN7O4:546.1657；Found:546.1662.
实施例7
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氯苯甲酰胺(Ⅰ-7)的合成
4-氯-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-7)的合成
以化合物Ⅺ(0.80g,3.04mmol)和对氯苯甲酰氯(0.80g,4.56mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体1.02g，产率83.6％，m.p.210-212℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.99-7.76(m,4H,ArH),7.60-7.45(m,2H,ArH,NH),7.32-7.26(m,1H,ArH),6.07(s,2H,OCH2O),1.36(s,12H,4CH3).
(R)-3-(4-氨基-3-(7-(4-氯苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-7)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-7(0.87g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体1.14g，m.p.120-122℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.35(s,1H,ArH),7.99(s,1H,NH),7.96-7.81(m,3H,ArH),7.48(d,J＝7.83Hz,2H,ArH),7.13(d,J＝8.43Hz,1H,ArH),6.12(s,2H,OCH2O),5.87(s,2H,NH2),4.92-4.77(m,1H,CHCH 2NBoc),4.46-4.23(m,1H,CHCH2NBoc),4.20-4.02(m,1H,CHCH 2NBoc),3.52-3.28(m,1H,NCH 2CH2),2.93-2.74(m,1H,NCH 2CH2),2.37-2.18(m,2H,NCH2CHCH 2),1.98-1.80(m,1H,NCH2CH 2),1.79-1.59(m,1H,NCH2CH 2),1.45(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氯苯甲酰胺(Ⅵ-7)的合成
以化合物Ⅴ-7(1.00g,1.69mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体777mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氯苯甲酰胺(Ⅰ-7)的合成
以化合物Ⅵ-7(500mg,1.02mmol)和丙烯酰氯(97mg,1.07mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体240mg，产率43.2％，m.p.159.5-161℃。1H-NMR(400MHz,CDCl3)δ(ppm):8.32(d,J＝11.08Hz,1H,ArH),8.13(s,1H,CONH),7.98-7.90(m,1H,ArH),7.87(d,J＝6.92Hz,2H,ArH),7.52(d,J＝7.12Hz,2H,ArH),7.10(d,J＝6.04Hz,1H,ArH),6.67-6.53(m,1H,CH＝CH2),6.35-6.23(m,1H,CH＝CH2),6.11(br,3H,OCH2O,NH),5.76-5.61(m,1H,CH＝CH2),4.95-4.82(m,1.5H,NCH 2CH),4.67-4.56(m,0.5H,NCH2CH),4.28-4.15(m,0.5H,NCH 2CH),4.08-3.97(m,0.5H,NCH 2CH),3.85-3.72(m,0.5H,NCH 2CH2),3.42-3.29(m,0.5H,NCH 2CH2),3.25-3.13(m,0.5H,NCH 2CH2),2.93-2.79(m,0.5H,NCH 2CH2),2.65(s,1H,NH2),2.47-2.32(m,1H,NCH2CHCH 2),2.31-2.18(m,1H,NCH2CHCH 2),2.04-1.92(m,1H,NCH2CH 2),1.80-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C27H25ClN7O4:546.1657；Found:546.1655.
实施例8
(R)-N1-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-N3-(2,2,2-三氟乙基)间苯二甲酰胺(Ⅰ-8)的合成
3-((7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-氨甲酰基)苯甲酸甲酯(Ⅳ-8)的合成
以化合物Ⅺ(1.00g,3.80mmol)和间苯二甲酸单甲酯(1.03g,5.72mmol)为原料，操作过程同化合物Ⅳ-2，得白色固体1.45g，产率89.7％，不经进一步纯化，直接投下一步。1H-NMR(300MHz,CDCl3)δ(ppm):8.51(s,1H,NH),8.22(d,J＝7.77Hz,1H,ArH),8.12(d,J＝7.89Hz,1H,ArH),7.91(s,1H,ArH),7.84(d,J＝8.43Hz,1H,ArH),7.59(t,J＝7.71Hz,1H,ArH),7.29(d,J＝8.49Hz,1H,ArH),6.08(s,2H,OCH2O),3.96(s,3H,CH3),1.37(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(3-甲氧羰基苯甲酰胺)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-8)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-8(1.15g,2.70mmol)为原料，操作过程同化合物Ⅴ-1，得灰色固体1.52g，产物不经纯化，直接投下一步。
(R)-3-((7-(4-氨基-1-(1-叔丁氧羰基)哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)氨基甲酰基)苯甲酸(Ⅴ-8-1)的合成
将化合物Ⅴ-8(1.40g,2.27mmol)、一水合氢氧化锂(0.14g,3.41mmol)和甲醇/水(12mL/4mL)混合，室温搅拌过夜。减压蒸去甲醇，加入水和乙酸乙酯，除去有机层，水层用2mol/L盐酸调pH至3-4，抽滤，烘干得1.13g白色固体，产率82.6％，m.p.168-170℃。
(R)-3-(4-氨基-3-(7-(3-((2,2,2-三氟乙基)氨甲酰基)苯甲酰胺)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-8-2)的合成
将Ⅴ-8-1(900mg,1.50mmol)、HOBt(243mg,1.80mmol)、EDCI(344mg,1.80mmol)溶于5mL DMF中，加入三乙胺(227mg,2.24mmol)和三氟乙胺(156mg,1.57mmol)，室温搅拌过夜。加入25mL水，乙酸乙酯萃取，有机层水洗(10mL×3),饱和氯化钠洗(10mL×3)，无水硫酸钠干燥。抽滤，滤液减压蒸干，残留物柱层析纯化(洗脱剂:二氯甲烷:甲醇＝100～40:1)得白色固体667mg，产率65.3％，m.p.143-145℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.40(s,1H,ArH),8.32(s,1H,NH),8.27(s,1H,ArH),8.04(q,J＝7.92Hz,2H,ArH),7.76(d,J＝7.92Hz,1H,ArH),7.56(t,J＝7.71Hz,1H,ArH),7.22(s,1H,NH),7.09(d,J＝8.79Hz,1H,ArH),6.06(s,2H,OCH2O),5.87(s,2H,NH2),4.88-4.74(m,1H,CHCH 2NBoc),4.37-4.25(m,1H,CHCH2NBoc),4.21-4.05(m,3H,CHCH 2NBoc,CH 2CF3),3.49-3.30(m,1H,NCH 2CH2),2.90-2.74(m,1H,NCH 2CH2),2.29-2.14(m,2H,NCH2CHCH 2),1.94-1.81(m,1H,NCH2CH 2),1.76-1.60(m,1H,NCH2CH 2),1.43(s,9H,3CH3)。
(R)-N1-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-N3-(2,2,2-三氟乙基)间苯二甲酰胺(Ⅵ-8)的合成
以化合物Ⅴ-8-2(550mg,0.81mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体430mg,产率91.62％，不经进一步纯化，直接投下一步。
(R)-N1-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-N3-(2,2,2-三氟乙基)间苯二甲酰胺(Ⅰ-8)的合成
以化合物Ⅵ-8(400mg,0.69mmol)和丙烯酰氯(65mg,0.72mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体231mg，产率52.8％，m.p.174-176℃。1H-NMR(300MHz,DMSO-d6)δ(ppm):10.43(s,1H,NH),9.30(s,1H,NH),8.50(s,1H,ArH),8.33-8.00(m,2H,ArH),7.66(s,1H,ArH),7.35-6.97(m,2H,ArH),6.95-6.55(m,2H,ArH,CH＝CH2),6.37-5.92(m,3H,CH＝CH2,OCH2O),5.83-5.49(m,1H,CH＝CH2),4.86-4.46(m,1.5H,NCH 2CH),4.37-3.91(m,3H,NCH 2CH,NHCH 2CF3),3.79-3.58(m,0.5H,NCH 2CH),3.07-2.84(m,1H,NCH 2CH2),2.36-2.03(m,2H,NCH 2CH2,NCH2CHCH 2),2.02-1.80(m,1H,NCH2CHCH 2),1.72-1.46(m,1H,NCH2CH 2),1.36-1.10(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C30H28F3N8O5:637.2135；Found:637.2134。
实施例9
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-三氟甲基苯甲酰胺(Ⅰ-9)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-三氟甲基苯甲酰胺(Ⅳ-9)的合成
以化合物Ⅺ(0.50g,1.90mmol)和4-三氟甲基苯甲酰氯(0.60g,2.85mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体654mg，产率79.1％，m.p.240-242℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.99(d,J＝8.16Hz,2H,ArH),7.88-7.81(m,2H,ArH,NH),7.76(d,J＝8.19Hz,2H,ArH),7.29(d,J＝8.52Hz,1H,ArH),6.08(s,2H,OCH2O),1.37(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(4-三氟甲基苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-9)的合成
以化合物Ⅲ-1(0.50g,1.13mmol)和Ⅳ-9(0.59g,1.35mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体0.62g，产率88.1％，m.p.140-142℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.38(s,1H,ArH),8.05(d,J＝8.13Hz,2H,ArH),8.01-7.95(m,2H,ArH,NH),7.81(d,J＝8.28Hz,2H,ArH),7.18(d,J＝8.73Hz,1H,ArH),6.16(s,2H,OCH2O),5.74(s,2H,NH2),4.93-4.81(m,1H,CHCH 2NBoc),4.42-4.27(m,1H,CHCH2NBoc),4.21-4.10(m,1H,CHCH 2NBoc),3.54-3.39(m,1H,NCH 2CH2),2.95-2.79(m,1H,NCH 2CH2),2.35-2.19(m,2H,NCH2CHCH 2),1.96-1.87(m,1H,NCH2CH 2),1.78-1.68(m,1H,NCH2CH 2),1.47(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-三氟甲基苯甲酰胺(Ⅵ-9)的合成
以化合物Ⅴ-9(550mg,0.88mmol)为原料，操作过程同化合物Ⅵ-1的合成过程，得淡黄色固体420mg，产率90.91％。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-三氟甲基苯甲酰胺(Ⅰ-9)的合成
以化合物Ⅵ-9(500mg,0.95mmol)和丙烯酰氯(103mg,1.14mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体289mg，产率52.4％，m.p.148.5-150℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.43-8.23(m,2H,ArH,NH),8.05(d,J＝7.62Hz,2H,ArH),7.92-7.81(m,1H,ArH),7.76(d,J＝7.44Hz,2H,ArH),7.20-7.04(m,1H,ArH),6.70-6.48(m,1H,CH＝CH2),6.35-6.19(m,1H,CH＝CH2),6.11(s,2H,OCH2O),5.96(s,1H,NH2),5.75-5.59(m,1H,CH＝CH2),4.98-4.75(m,1.5H,NCH 2CH),4.67-4.48(m,0.5H,NCH2CH),4.30-4.13(m,0.5H,NCH 2CH),4.09-3.92(m,0.5H,NCH 2CH),3.88-3.67(m,0.5H,NCH 2CH2),3.45-3.28(m,0.5H,NCH 2CH2),3.26-3.09(m,0.5H,NCH 2CH2),2.96-2.80(m,0.5H,NCH 2CH2),2.50-2.31(m,1H,NCH2CHCH 2),2.29-2.18(m,2H,NCH2CHCH 2,NH2),2.07-1.89(m,1H,NCH2CH 2),1.81-1.60(m,1H,NCH2CH 2)；13C-NMR(75MHz,DMSO-d6)δ(ppm):164.55,163.98,158.03,155.89,155.66,153.71,145.90,140.95,138.29,137.78,128.73,128.32,127.29,125.69,125.40,122.11,120.95,118.82,111.82,101.72,98.64,52.91(0.5C),52.19(0.5C),49.19(0.5C),48.70(0.5C),45.65(0.5C),45.10(0.5C),30.38(0.5C),29.57(0.5C),26.78(0.5C),24.81(0.5C)；HRMS(ESI):m/z[M+H]+.Calcd for C28H25F3N7O4:580.1920；Found:580.1918。
实施例10
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯甲酰胺(Ⅰ-10)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯甲酰胺(Ⅳ-10)的合成
以化合物Ⅺ(1.50g,5.70mmol)和4-甲氧基苯甲酰氯(1.46g,8.55mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体1.92g，产率84.1％，m.p.176-178℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.93-7.81(m,3H,ArH),7.78(br,1H,NH),7.28(d,J＝8.31Hz,1H,ArH),6.97(d,J＝8.58Hz,2H,ArH),6.06(s,2H,OCH2O),3.87(s,3H,OCH3),1.36(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(4-甲氧基苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-10)的合成
以化合物Ⅲ-1(1.20g,2.70mmol)和Ⅳ-10(1.29g,3.24mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体1.49g，产率93.7％，m.p.104-106℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.38(s,1H,ArH),8.01(d,J＝8.70Hz,1H,ArH),7.90(d,J＝8.85Hz,2H,ArH),7.87(br,1H,NH),7.15(d,J＝8.70Hz,1H,ArH),7.02(d,J＝8.82Hz,2H,ArH),6.14(s,2H,OCH2O),5.75(s,2H,NH2),4.94-4.80(m,1H,CHCH 2NBoc),4.44-4.25(m,1H,CHCH2NBoc),4.23-4.06(m,1H,CHCH 2NBoc),3.91(s,3H,OCH3),3.56-3.36(m,1H,NCH 2CH2),2.93-2.78(m,1H,NCH 2CH2),2.34-2.17(m,2H,NCH2CHCH 2),1.98-1.83(m,2H,NCH2CH 2),1.47(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯甲酰胺(Ⅵ-10)的合成
以化合物Ⅴ-10(1.27g,2.17mmol)为原料,操作过程同化合物Ⅵ-1,得淡黄色固体1.04g,产率98.01％。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯甲酰胺(Ⅰ-10)的合成
以化合物Ⅵ-10(100mg,0.21mmol)和丙烯酰氯(19mg,0.22mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体89mg，产率80.1％，m.p.216-218℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.35(s,1H,ArH),8.02-7.93(m,2H,ArH,NH),7.90(d,J＝7.68Hz,2H,ArH),7.12(d,J＝8.16Hz,1H,ArH),7.00(d,J＝7.74Hz,2H,ArH),6.71-6.51(m,1H,CH＝CH2),6.38-6.22(m,1H,CH＝CH2),6.12(s,2H,OCH2O),5.90(s,1H,NH2),5.77-5.61(m,1H,CH＝CH2),4.96-4.80(m,1.5H,NCH 2CH),4.71-4.53(m,0.5H,NCH2CH),4.29-4.16(m,0.5H,NCH 2CH),4.08-3.98(m,0.5H,NCH 2CH),3.90(s,3H,OCH3),3.82-3.69(m,0.5H,NCH 2CH2),3.51-3.32(m,0.5H,NCH 2CH2),3.29-3.10(m,0.5H,NCH 2CH2),2.97-2.75(m,0.5H,NCH 2CH2),2.51-2.35(m,1H,NCH2CHCH 2),2.35-2.14(m,2H,NCH2CHCH 2,NH2),2.09-1.89(m,1H,NCH2CH 2),1.83-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C28H28N7O5:542.2152；Found:542.2156。
实施例11
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-叔丁基苯甲酰胺(Ⅰ-11)的合成
4-叔丁基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-11)的合成
以化合物Ⅺ(1.00g,3.80mmol)和4-叔丁基苯甲酸(1.02g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得白色固体982mg，产率61.0％，m.p.170-172℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.91(d,J＝8.52Hz,1H,ArH),7.86(s,1H,NHCO),7.82(d,J＝8.46Hz,2H,ArH),7.51(d,J＝8.46Hz,2H,ArH),7.28(d,J＝8.52Hz,1H,ArH),6.07(s,2H,OCH2O),1.36(s,12H,4CH3),1.35(s,9H,C(CH3)3)。
(R)-3-(4-氨基-3-(7-(4-叔丁基苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-11)的合成
以化合物Ⅲ-1(0.75g,1.69mmol)和Ⅳ-11(0.86g,2.03mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体969mg，产率93.5％，m.p.140-142℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.39(s,1H,ArH),8.07-7.99(m,2H,ArH,NH),7.89(d,J＝8.34Hz,2H,ArH),7.56(d,J＝8.31Hz,2H,ArH),7.16(d,J＝8.67Hz,1H,ArH),6.16(s,2H,OCH2O),5.93(s,1H,NH2),4.96-4.82(m,1H,CHCH 2NBoc),4.49-4.10(m,2H,CHCH 2NBoc),3.62-3.32(m,1H,NCH 2CH2),2.97-2.79(m,1H,NCH2CH2),2.27-2.14(m,3H,NCH2CHCH 2,NH2),1.99-1.87(m,1H,NCH2CH 2),1.80-1.68(m,1H,NCH2CH 2),1.48(s,9H,3CH3),1.40(s,9H,3CH3)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-叔丁基苯甲酰胺(Ⅵ-11)的合成
以化合物Ⅴ-11(900mg,1.47mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体697mg，产率92.5％，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-叔丁基苯甲酰胺(Ⅰ-11)的合成
以化合物Ⅵ-11(600mg,1.17mmol)和丙烯酰氯(111mg,1.23mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体242mg，产率36.5％，m.p.136-138℃。1H-NMR(400MHz,CDCl3)δ(ppm):8.32(d,J＝11.08Hz,1H,ArH),8.12(s,1H,NH),7.98-7.89(m,1H,ArH),7.86(d,J＝6.92Hz,2H,ArH),7.52(d,J＝7.12Hz,2H,ArH),7.10(d,J＝6.04Hz,1H,ArH),6.68-6.51(m,1H,CH＝CH2),6.36-6.21(m,1H,CH＝CH2),6.17-6.01(m,3H,NH2,OCH2O),5.76-5.60(m,1H,CH＝CH2),4.95-4.78(m,1.5H,NCH 2CH),4.67-4.50(m,0.5H,NCH2CH),4.29-4.14(m,0.5H,NCH 2CH),4.09-3.95(m,0.5H,NCH 2CH),3.84-3.69(m,0.5H,NCH 2CH2),3.41-3.27(m,0.5H,NCH 2CH2),3.24-3.10(m,0.5H,NCH 2CH2),2.92-2.78(m,0.5H,NCH 2CH2),2.65(s,1H,NH2),2.48-2.31(m,1H,NCH2CHCH 2),2.30-2.16(m,1H,NCH2CHCH 2),2.04-1.89(m,1H,NCH2CH 2),1.79-1.61(m,1H,NCH2CH 2),1.35(s,9H,3CH3)；HRMS(ESI):m/z[M+H]+.Calcd forC31H34N7O4:568.2672；Found:568.2674。
实施例12
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3,4-二甲氧基苯甲酰胺(Ⅰ-12)的合成
3,4-二甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-12)的合成
以化合物Ⅺ(1.00g,3.80mmol)和3,4-二甲氧基苯甲酰氯(1.14g,5.70mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体926mg，产率57.2％，m.p.166-168℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.90-7.82(m,2H,ArH,NHCO),7.51(s,1H,ArH),7.41(d,J＝8.31Hz,1H,ArH),7.28(d,J＝8.04Hz,1H,ArH),6.91(d,J＝8.34Hz,1H,ArH),6.07(s,2H,OCH2O),3.95(s,3H,OCH3),3.95(s,3H,OCH3),1.36(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(3,4-二甲氧基苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-12)的合成
以化合物Ⅲ-1(0.70g,1.58mmol)和Ⅳ-12(0.81g,1.89mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体731mg，产率75.1％，m.p.120-122℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.37(s,1H,ArH),8.00(d,J＝8.94Hz,1H,ArH),7.88(s,1H,ArH),7.54(s,1H,NH),7.44(d,J＝8.37Hz,1H,ArH),7.15(d,J＝8.91Hz,1H,ArH),6.94(d,J＝8.01Hz,1H,ArH),6.13(s,2H,OCH2O),5.78(s,2H,NH2),4.92-4.78(m,1H,CHCH 2NBoc),4.38-4.24(m,1H,CHCH2NBoc),4.20-4.08(m,1H,CHCH 2NBoc),3.98(s,3H,OCH 3),3.97(s,3H,OCH 3),3.52-3.37(m,1H,NCH 2CH2),2.91-2.77(m,1H,NCH 2CH2),2.33-2.24(m,1H,NCH2CHCH 2),2.23-2.14(m,1H,NCH2CHCH 2),1.96-1.84(m,1H,NCH2CH 2),1.77-1.65(m,1H,NCH2CH 2),1.45(s,9H,NBoc).
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3,4-二甲氧基苯甲酰胺(Ⅵ-12)的合成
以化合物Ⅴ-12(700mg,1.13mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体587mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3,4-二甲氧基苯甲酰胺(Ⅰ-12)的合成
以化合物Ⅵ-12(537mg,1.04mmol)和丙烯酰氯(99mg,1.09mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体309mg，产率52.1％，m.p.164-165℃。1H-NMR(400MHz,CDCl3)δ(ppm):8.41-8.25(m,1H,ArH),8.05(s,1H,NH),7.94-7.87(m,1H,ArH),7.56-7.51(m,1H,ArH),7.49-7.44(m,1H,ArH),7.11(d,J＝8.64Hz,1H,ArH),6.93(d,J＝8.40Hz,1H,ArH),6.68-6.52(m,1H,CH＝CH2),6.36-6.23(m,1H,CH＝CH2),6.12(s,2H,OCH2O),5.95(br,1H,NH2),5.78-5.60(m,1H,CH＝CH2),4.94-4.83(m,1.5H,NCH 2CH),4.66-4.55(m,0.5H,NCH2CH),4.26-4.17(m,0.5H,NCH 2CH),4.09-4.00(m,0.5H,NCH 2CH),3.96(s,3H,OCH3),3.96(s,3H,OCH3),3.83-3.73(m,0.5H,NCH 2CH2),3.41-3.31(m,0.5H,NCH 2CH2),3.24-3.13(m,0.5H,NCH 2CH2),2.94-2.81(m,0.5H,NCH 2CH2),2.45-2.34(m,1H,NCH2CHCH 2),2.29-2.23(m,2H,NCH2CHCH 2,NH2),2.02-1.94(m,1H,NCH2CH 2),1.79-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H30N7O6:572.2258；Found:572.2252。
实施例13
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲基氨基)苯甲酰胺(Ⅰ-13)的合成
4-(二甲氨基)-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-13)的合成
以化合物Ⅺ(1.00g,3.80mmol)和4-二甲氨基苯甲酰氯(1.05g,5.70mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体950mg，产率60.9％，不经进一步纯化，直接投下一步。
(R)-3-(4-氨基-3-(7-(4-(二甲氨基)苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-13)的合成
以化合物Ⅲ-1(0.60g,1.35mmol)和Ⅳ-13(0.67g,1.62mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体678mg，产率83.5％，m.p.138-140℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.36(s,1H,ArH),8.04(d,J＝9.03Hz,1H,ArH),7.89-7.76(m,3H,ArH,NH),7.12(d,J＝7.98Hz,1H,ArH),6.73(d,J＝8.61Hz,2H,ArH),6.12(s,2H,OCH2O),5.75(s,2H,NH2),4.90-4.79(m,1H,CHCH 2NBoc),4.40-4.26(m,1H,CHCH2NBoc),4.22-4.06(m,1H,CHCH 2NBoc),3.54-3.35(m,1H,NCH 2CH2),3.07(s,6H,N(CH 3)2),2.90-2.74(m,1H,NCH 2CH2),2.34-2.15(m,2H,NCH2CHCH 2),1.99-1.82(m,2H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲氨基)苯甲酰胺(Ⅵ-13)的合成
以化合物Ⅴ-13(850mg,1.42mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体588mg，产率83.0％，不经进一步纯化,直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲基氨基)苯甲酰胺(Ⅰ-13)的合成
以化合物Ⅵ-13(540mg,1.08mmol)和丙烯酰氯(103mg,1.13mmol)为原料，操作过程同目标化合物Ⅰ-1的合成，得白色固体342mg，产率57.2％，m.p.160-162℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.33(s,1H,ArH),8.04-7.88(m,2H,ArH,NH),7.81(d,J＝6.66Hz,2H,ArH),7.09(d,J＝8.07Hz,1H,ArH),6.71(d,J＝6.96Hz,2H,ArH),6.65-6.52(m,1H,CH＝CH2),6.36-6.21(m,1H,CH＝CH2),6.17-5.99(m,3H,NH2,OCH2O),5.76-5.59(m,1H,CH＝CH2),4.96-4.79(m,1.5H,NCH 2CH),4.69-4.57(m,0.5H,NCH2CH),4.28-4.15(m,0.5H,NCH 2CH),4.08-3.96(m,0.5H,NCH 2CH),3.85-3.70(m,0.5H,NCH 2CH2),3.43-3.28(m,0.5H,NCH 2CH2),3.24-3.14(m,0.5H,NCH 2CH2),3.06(s,6H,2CH3),2.89-2.72(m,1.5H,NCH 2CH2,NH2),2.47-2.31(m,1H,NCH2CHCH 2),2.30-2.16(m,1H,NCH2CHCH 2),2.04-1.89(m,1H,NCH2CH 2),1.80-1.61(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H31N8O4:555.2468；Found:555.2466。
实施例14
N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲基氨基)苯甲酰胺(Ⅰ-14)的合成
3-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅲ-2)的合成
以化合物Ⅶ-1(3.00g,11.49mmol)和1-叔丁氧羰基-3-羟基哌啶(Ⅷ-2)(4.63g,22.99mmol)为原料，操作过程同化合物Ⅲ-1，得3.91g白色固体，产率76.5％，m.p.176-178℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.31(s,1H,ArH),6.17(s,2H,NH2),4.82-4.68(m,1H,CHCH 2N),4.22-4.05(m,1H,CHCH2N),3.79-3.67(m,1H,CHCH 2N),3.22-3.02(m,1H,CHCH2CH2CH 2N),2.91-2.74(m,1H,CHCH2CH2CH 2N),2.19-2.08(m,2H,CHCH 2CH2CH2N),1.95-1.81(m,2H,CHCH2CH 2CH2N),1.45(s,9H,NBoc)。
3-(4-氨基-3-(7-(4-(二甲氨基)苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-14)的合成
以化合物Ⅲ-2(0.95g,2.14mmol)和Ⅳ-13(1.05g,2.57mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体890mg，产率69.5％，m.p.140-142℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.38(s,1H,ArH),8.04(d,J＝8.73Hz,1H,ArH),7.89(s,1H,NHCO),7.85(d,J＝8.88Hz,2H,ArH),7.15(d,J＝8.70Hz,1H,ArH),6.75(d,J＝8.94Hz,2H,ArH),6.15(s,2H,OCH2O),5.94(s,2H,NH2),4.94-4.81(m,1H,NCH 2CH),4.33-4.12(m,2H,NCH 2CH),3.59-3.37(m,1H,NCH 2CH2),3.10(s,6H,N(CH3)2),2.93-2.81(m,1H,NCH 2CH2),2.27-2.19(m,2H,NCH2CHCH 2),1.98-1.87(m,1H,NCH2CH 2),1.78-1.66(m,1H,NCH2CH 2),1.48(s,9H,NBoc)。
N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲氨基)苯甲酰胺(Ⅵ-14)的合成
以化合物Ⅴ-14(850mg,1.42mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体436mg，产率61.6％，不经进一步纯化，直接投下一步。
N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲基氨基)苯甲酰胺(Ⅰ-14)的合成
以化合物Ⅵ-14(420mg,0.84mmol)和丙烯酰氯(80mg,0.88mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体213mg，产率45.7％，m.p.160-162℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.33(s,1H,ArH),8.03(d,J＝8.97Hz,1H,ArH),7.86-7.76(m,3H,ArH,NH),7.11(d,J＝8.82Hz,1H,ArH),6.71(d,J＝7.32Hz,2H,ArH),6.67-6.52(m,1H,CH＝CH2),6.36-6.22(m,1H,CH＝CH2),6.11(s,2H,OCH2O),5.97(br,1H,NH2),5.77-5.63(m,1H,CH＝CH2),4.97-4.80(m,1.5H,NCH 2CH),4.72-4.58(m,0.5H,NCH2CH),4.30-4.17(m,0.5H,NCH 2CH),4.11-3.99(m,0.5H,NCH 2CH),3.85-3.65(m,0.5H,NCH 2CH2),3.48-3.34(m,0.5H,NCH 2CH2),3.26-3.13(m,0.5H,NCH 2CH2),3.06(s,6H,N(CH3)2),2.93-2.70(m,1.5H,NCH 2CH2,NH2),2.46-2.32(m,1H,NCH2CHCH 2),2.31-2.19(m,1H,NCH2CHCH 2),2.06-1.92(m,1H,NCH2CH 2),1.83-1.65(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H31N8O4:555.2468；Found:555.2470。
实施例15
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二乙基氨基)苯甲酰胺(Ⅰ-15)的合成
4-(二乙氨基)-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅳ-15)的合成
以化合物Ⅺ(1.00g,3.80mmol)和4-二乙氨基苯甲酸(1.10g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得棕色油状物2.04g，不经进一步纯化，直接投下一步。
(R)-3-(4-氨基-3-(7-(4-(二乙氨基)苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-15)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-15(0.95g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体657mg，产率58.0％，m.p.116-118℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.35(s,1H,ArH),8.06(d,J＝8.25Hz,1H,ArH),7.83-7.76(m,3H,ArH,NH),7.12(d,J＝8.52Hz,1H,ArH),6.69(d,J＝8.43Hz,2H,ArH),6.12(s,2H,OCH2O),6.03(s,2H,NH2),4.89-4.78(m,1H,CHCH 2NBoc),4.37-4.26(m,1H,CHCH2NBoc),4.17-4.10(m,1H,CHCH 2NBoc),3.47-3.39(m,5H,NCH 2CH2,N(CH 2CH3)2),2.87-2.80(m,1H,NCH 2CH2),2.25-2.15(m,2H,NCH2CHCH 2),1.91-1.84(m,1H,NCH2CH 2),1.72-1.66(m,1H,NCH2CH 2),1.45(s,9H,NBoc),1.24-1.19(m,6H,N(CH2CH 3)2)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二乙氨基)苯甲酰胺(Ⅵ-15)的合成
以化合物Ⅴ-15(657mg,1.05mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体328mg，产率59.4％，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二乙基氨基)苯甲酰胺(Ⅰ-15)的合成
以化合物Ⅵ-15(300mg,0.57mmol)和丙烯酰氯(54mg,0.60mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体209mg，产率63.2％，m.p.158-160℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.34(s,1H,ArH),8.06-7.95(m,1H,ArH),7.92-7.85(m,1H,ArH),7.85-7.73(m,2H,ArH,NH),7.18-7.03(m,1H,ArH),6.77-6.51(m,3H,ArH,CH＝CH2),6.39-6.22(m,1H,CH＝CH2),6.11(s,2H,OCH2O),6.00(s,1H,NH2),5.79-5.61(m,1H,CH＝CH2),4.98-4.79(m,1.5H,NCH 2CH),4.72-4.55(m,0.5H,NCH2CH),4.31-4.16(m,0.5H,NCH 2CH),4.12-3.96(m,0.5H,NCH 2CH),3.87-3.71(m,0.5H,NCH 2CH2),3.53-3.30(m,4H,N(CH 2CH3)2),3.28-3.12(m,0.5H,NCH 2CH2),2.94-2.77(m,0.5H,NCH 2CH2),2.46-2.20(m,3.5H,NCH 2CH2,NCH2CHCH 2,NH2),2.08-1.91(m,1H,NCH2CH 2),1.84-1.63(m,1H,NCH2CH 2),1.31-1.15(m,6H,N(CH2CH 3)2)；HRMS(ESI):m/z[M+H]+.Calcd for C31H35N8O4:583.2781；Found:583.2777。
实施例16
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯并[b]噻吩-2-甲酰胺(Ⅰ-16)的合成
3-氯-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯并[b]噻吩-2-甲酰胺(Ⅳ-16)的合成
以化合物Ⅺ(800mg,3.04mmol)和3-氯苯并[b]噻吩-2-羧酸(1.00g,4.70mmol)为原料，操作过程同化合物Ⅳ-2，得黄色固体1.02g，产率73.4％，不经进一步纯化，直接投下一步。(R)-3-(4-氨基-3-(7-(3-氯苯并[b]噻吩-2-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-16)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-16(0.99g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体998mg，产率85.3％，m.p.218-220℃。1H-NMR(300MHz,CDCl3)δ(ppm):9.13(s,1H,NH),8.36(s,1H,ArH),8.08(d,J＝8.85Hz,1H,ArH),7.97-7.85(m,2H,ArH),7.58-7.50(m,2H,ArH),7.16(d,J＝8.73Hz,1H,ArH),6.19(s,2H,OCH2O),5.94(s,2H,NH2),4.94-4.76(m,1H,CHCH 2NBoc),4.42-4.24(m,1H,CHCH2NBoc),4.22-4.07(m,1H,CHCH 2NBoc),3.56-3.31(m,1H,NCH 2CH2),2.93-2.74(m,1H,NCH 2CH2),2.51-2.35(m,1H,NCH2CHCH 2),2.24-2.12(m,1H,NCH2CHCH 2),1.96-1.80(m,1H,NCH2CH 2),1.78-1.64(m,1H,NCH2CH 2),1.45(s,9H,3CH3)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯并[b]噻吩-2-甲酰胺(Ⅵ-16)的合成
以化合物Ⅴ-16(1.77g,1.47mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体797mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-氯苯并[b]噻吩-2-甲酰胺(Ⅰ-16)的合成
以化合物Ⅵ-16(500mg,0.91mmol)和丙烯酰氯(87mg,0.96mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体312mg，产率56.8％，m.p.172-174℃。1H-NMR(400MHz,CDCl3)δ(ppm):9.13(s,1H,NH),8.36(s,1H,ArH),8.08(d,J＝8.64Hz,1H,ArH),7.97-7.91(m,1H,ArH),7.91-7.85(m,1H,ArH),7.59-7.48(m,2H,ArH),7.15(d,J＝8.68Hz,1H,ArH),6.67-6.54(m,1H,CH＝CH2),6.36-6.24(m,1H,CH＝CH2),6.19(s,2H,OCH2O),5.89(s,1H,NH2),5.77-5.61(m,1H,CH＝CH2),4.96-4.80(m,1.5H,NCH 2CH),4.69-4.59(m,0.5H,NCH2CH),4.28-4.16(m,0.5H,NCH 2CH),4.09-3.97(m,0.5H,NCH 2CH),3.86-3.73(m,0.5H,NCH 2CH2),3.47-3.34(m,0.5H,NCH 2CH2),3.26-3.15(m,0.5H,NCH 2CH2),2.93-2.80(m,0.5H,NCH 2CH2),2.50-2.34(m,1H,NCH2CHCH 2),2.31-2.22(m,2H,NCH2CHCH 2,NH2),2.06-1.93(m,1H,NCH2CH 2),1.81-1.66(m,1H,NCH2CH 2)；13C-NMR(101MHz,CDCl3)δ(ppm):165.71,158.68,157.87,155.78,155.56,154.14,145.15,138.71,138.35,137.56,136.90,132.84,127.96,127.70,125.71,123.42,123.27,122.93,122.22,119.39,115.63,111.52,102.26,99.65,53.75(0.5C),52.65(0.5C),49.97(0.5C),46.02(0.5C),45.87(0.5C),42.12(0.5C),30.31(0.5C),30.05(0.5C),25.25(0.5C),23.99(0.5C)；HRMS(ESI):m/z[M+H]+.Calcd forC29H25ClN7O4S:602.1377；Found:602.1378.
实施例17
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅰ-17)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅳ-17)的合成
以化合物Ⅺ(1.00g,3.80mmol)和1-萘甲酰氯(1.09g,5.70mmol)为原料，操作过程同化合物Ⅳ-1，得红棕色固体1.47g，产率93.0％，m.p.174-176℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.39(d,J＝7.65Hz,1H,ArH),7.95(d,J＝7.92Hz,2H,ArH),7.88(d,J＝6.99Hz,1H,ArH),7.78(s,1H,NHCO),7.74(d,J＝6.87Hz,1H,ArH),7.60-7.52(m,2H,ArH),7.52-7.42(m,1H,ArH),7.31(d,J＝8.31Hz,1H,ArH),6.01(s,2H,OCH2O),1.37(s,12H,4CH3)。
(R)-3-(3-(7-(1-萘甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-17)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-17(0.90g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体751mg，产率68.6％，m.p.144-146℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.45-8.40(m,1H,ArH),8.36(s,1H,ArH),8.14-8.07(m,1H,ArH),8.00(d,J＝8.22Hz,1H,ArH),7.95-7.90(m,1H,ArH),7.87(s,1H,NH),7.83-7.77(m,1H,ArH),7.62-7.56(m,2H,ArH),7.56-7.52(m,1H,ArH),7.18(d,J＝8.67Hz,1H,ArH),6.10(s,2H,OCH2O),5.91(s,2H,NH2),4.92-4.78(m,1H,CHCH 2NBoc),4.39-4.23(m,1H,CHCH2NBoc),4.21-4.07(m,1H,CHCH 2NBoc),3.56-3.32(m,1H,NCH 2CH2),2.92-2.75(m,1H,NCH 2CH2),2.23-2.14(m,2H,NCH2CHCH 2),1.97-1.82(m,1H,NCH2CH 2),1.77-1.63(m,1H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅵ-17)的合成
以化合物Ⅴ-17(700mg,1.15mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体498mg，产率85.2％，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅰ-17)的合成
以化合物Ⅵ-17(441mg,0.87mmol)和丙烯酰氯(83mg,0.91mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体214mg，产率43.8％，m.p.172.0-174℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.42(d,J＝7.98Hz,1H,ArH),8.35(s,1H,ArH),8.09(d,J＝7.38Hz,1H,ArH),8.00(d,J＝8.16Hz,1H,ArH),7.96-7.87(m,2H,ArH,NH),7.80(d,J＝6.72Hz,1H,ArH),7.68-7.47(m,3H,ArH),7.17(d,J＝8.55Hz,1H,ArH),6.68-6.51(m,1H,CH＝CH2),6.34-6.21(m,1H,CH＝CH2),6.10(s,2H,OCH2O),5.88(s,1H,NH2),5.75-5.61(m,1H,CH＝CH2),4.98-4.80(m,1.5H,NCH 2CH),4.67-4.54(m,0.5H,NCH2CH),4.28-4.14(m,0.5H,NCH 2CH),4.07-3.94(m,0.5H,NCH 2CH),3.84-3.68(m,0.5H,NCH 2CH2),3.42-3.29(m,0.5H,NCH 2CH2),3.24-3.09(m,0.5H,NCH 2CH2),2.94-2.78(m,0.5H,NCH 2CH2),2.47-2.33(m,1H,NCH2CHCH 2),2.30-2.19(m,1H,NCH2CHCH 2),2.06(s,1H,NH2),2.02-1.92(m,1H,NCH2CH 2),1.82-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C31H28N7O4:562.2203；Found:562.2199。
实施例18
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅰ-18)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅳ-18)的合成
以化合物Ⅺ(1.00g,3.80mmol)和2-萘甲酰氯(1.09g,5.70mmol)为原料，操作过程同化合物Ⅳ-1，得白色固体1.51g，产率95.2％，m.p.152-154℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.40(s,1H,NH),8.02-7.88(m,6H,ArH),7.64-7.55(m,2H,ArH),7.31(d,J＝8.58Hz,1H,ArH),6.11(s,2H,OCH2O),1.37(s,12H,4CH3)。
(R)-3-(3-(7-(2-萘甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-18)的合成
以化合物Ⅲ-1(0.75g,1.69mmol)和Ⅳ-18(0.85g,2.03mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体757mg，产率73.8％，m.p.118-120℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.37(s,1H,ArH),8.12-8.04(m,2H,ArH,NH),8.02-7.89(m,4H,ArH),7.67-7.55(m,2H,ArH),7.17(d,J＝8.76Hz,1H,ArH),6.16(s,2H,OCH2O),5.76(s,2H,NH2),4.94-4.78(m,1H,CHCH 2NBoc),4.42-4.24(m,1H,CHCH2NBoc),4.21-4.04(m,1H,CHCH 2NBoc),3.57-3.37(m,1H,NCH 2CH2),2.92-2.75(m,1H,NCH 2CH2),2.34-2.14(m,2H,NCH2CHCH 2),1.95-1.82(m,1H,NCH2CH 2),1.77-1.62(m,1H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅵ-18)的合成
以化合物Ⅴ-18(700mg,1.15mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体448mg，产率76.6％。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅰ-18)的合成
以化合物Ⅵ-18(420mg,0.83mmol)和丙烯酰氯(79mg,0.87mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体247mg，产率53.1％，m.p.172.5-174℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.39-8.30(m,1H,ArH),8.30-8.22(m,1H,ArH),8.05-7.86(m,4H,ArH),7.68-7.53(m,2H,ArH),7.14(d,J＝8.25Hz,1H,ArH),6.68-6.51(m,1H,CH＝CH2),6.37-6.22(m,1H,CH＝CH2),6.14(s,2H,OCH2O),5.97(br,1H,NH2),5.77-5.61(m,1H,CH＝CH2),4.97-4.77(m,1.5H,NCH 2CH),4.68-4.55(m,0.5H,NCH2CH),4.27-4.15(m,0.5H,NCH 2CH),4.09-3.95(m,0.5H,NCH 2CH),3.86-3.69(m,0.5H,NCH 2CH2),3.44-3.29(m,0.5H,NCH 2CH2),3.26-3.09(m,0.5H,NCH 2CH2),2.93-2.76(m,0.5H,NCH 2CH2),2.49-2.31(m,1H,NCH2CHCH 2),2.30-2.11(m,2H,NCH2CHCH 2,NH2),2.03-1.91(m,1H,NCH2CH 2),1.79-1.62(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C31H28N7O4:562.2203；Found:562.2205。
实施例19
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲基-1-萘甲酰胺(Ⅰ-19)的合成
4-甲基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅳ-19)的合成
以化合物Ⅺ(1.00g,3.80mmol)和4-甲基-1-萘甲酸(1.06g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得淡黄色固体1.52g，产率92.7％，m.p.142-144℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.48-8.39(m,1H,ArH),8.09-8.01(m,1H,ArH),8.00-7.92(m,1H,ArH),7.71(s,1H,NHCO),7.65(d,J＝6.87Hz,1H,ArH),7.61-7.53(m,2H,ArH),7.38-7.27(m,2H,ArH),6.02(s,2H,OCH2O),2.74(s,3H,CH3),1.37(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(4-甲基-1-萘甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-19)的合成
以化合物Ⅲ-1(0.73g,1.65mmol)和Ⅳ-19(1.07g,2.48mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体719mg，产率70.0％，m.p.140-142℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.48-8.38(m,1H,ArH),8.29(s,1H,ArH),8.22(s,1H,NH),8.07-7.98(m,1H,ArH),7.97-7.88(m,1H,ArH),7.64(d,J＝7.11Hz,1H,ArH),7.60-7.49(m,2H,ArH),7.28(d,J＝7.35Hz,1H,ArH),7.10(d,J＝8.49Hz,1H,ArH),6.24(br,2H,NH2),6.03(s,2H,OCH2O),4.86-4.73(m,1H,CHCH 2NBoc),4.41-4.22(m,1H,CHCH2NBoc),4.17-3.99(m,1H,CHCH 2NBoc),3.52-3.24(m,1H,NCH 2CH2),2.82-2.61(m,4H,NCH 2CH2,CH3),2.31-2.07(m,2H,NCH2CHCH 2),1.92-1.76(m,1H,NCH2CH 2),1.74-1.57(m,1H,NCH2CH 2),1.44(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲基-1-萘甲酰胺(Ⅵ-19)的合成
以化合物Ⅴ-19(700mg,1.13mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体548mg，产率93.4％，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲基-1-萘甲酰胺(Ⅰ-19)的合成
以化合物Ⅵ-19(500mg,0.96mmol)和丙烯酰氯(91mg,1.01mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体289mg，产率53.3％，m.p.178-179℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.31(d,J＝7.62Hz,1H,ArH),8.21-7.92(m,3H,ArH,NH),7.68(d,J＝6.48Hz,1H,ArH),7.64-7.49(m,2H,ArH),7.33(d,J＝6.09Hz,1H,ArH),7.13(d,J＝7.17Hz,1H,ArH),6.66-6.48(m,1H,CH＝CH2),6.31-6.20(m,1H,CH＝CH2),6.17-5.98(m,3H,OCH2O,NH2),5.75-5.57(m,1H,CH＝CH2),4.95-4.76(m,1.5H,NCH 2CH),4.67-4.50(m,0.5H,NCH2CH),4.29-4.09(m,0.5H,NCH 2CH),4.08-3.89(m,0.5H,NCH 2CH),3.83-3.64(m,0.5H,NCH 2CH2),3.42-3.26(m,0.5H,NCH 2CH2),3.22-3.08(m,0.5H,NCH 2CH2),2.90-2.79(m,0.5H,NCH 2CH2),2.73(s,3H,CH3),2.56-2.17(m,3H,NCH2CHCH 2,NH2),2.03-1.87(m,1H,NCH2CH 2),1.78-1.58(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C32H30N7O4:576.2359；Found:576.2357。
实施例20
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5,6,7,8-四氢化萘-1-甲酰胺(Ⅰ-20)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5,6,7,8-四氢化萘-1-甲酰胺(Ⅳ-20)的合成
以化合物Ⅺ(1.00g,3.80mmol)和5,6,7,8-四氢-1-萘甲酸(1.00g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得白色固体1.51g，产率94.4％，m.p.168-170℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.92(d,J＝8.37Hz,1H,ArH),7.47(s,1H,NHCO),7.33-7.27(m,2H,ArH),7.21-7.14(m,2H,ArH),6.04(s,2H,OCH2O),3.02-2.77(m,4H,CH 2CH2CH2CH 2),1.88-1.73(m,4H,CH2CH 2CH 2CH2),1.36(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(5,6,7,8-四氢化萘-1-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-20)的合成
以化合物Ⅲ-1(0.75g,1.69mmol)和Ⅳ-20(0.85g,2.03mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体784mg，产率75.9％，m.p.150-152℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.36(s,1H,ArH),8.05(d,J＝8.76Hz,1H,ArH),7.56(s,1H,NH),7.37-7.30(m,1H,ArH),7.25-7.10(m,3H,ArH),6.10(s,2H,OCH2O),5.80(s,2H,NH2),4.91-4.78(m,1H,CHCH 2NBoc),4.41-4.22(m,1H,CHCH2NBoc),4.21-4.06(m,1H,CHCH 2NBoc),3.53-3.33(m,1H,NCH 2CH2),3.05-2.91(m,2H,CH2C),2.90-2.76(m,3H,CH2C,NCH 2CH2),2.33-2.15(m,2H,NCH2CHCH 2),1.96-1.86(m,1H,NCH2CH 2),1.86-1.76(m,4H,CCH2CH 2CH 2CH2C),1.74-1.63(m,1H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5,6,7,8-四氢化萘-1-甲酰胺(Ⅵ-20)的合成
以化合物Ⅴ-20(700mg,1.14mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体472mg，产率80.62％。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5,6,7,8-四氢化萘-1-甲酰胺(Ⅰ-20)的合成
以化合物Ⅵ-20(420mg,0.82mmol)和丙烯酰氯(78mg,0.86mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体316mg，产率68.1％，m.p.158-160℃。1H-NMR(400MHz,CDCl3)δ(ppm):8.33(s,1H,ArH),8.11-7.92(m,1H,ArH),7.63(s,1H,NH),7.38-7.29(m,1H,ArH),7.24-7.15(m,2H,ArH),7.12(d,J＝8.40Hz,1H,ArH),6.67-6.50(m,1H,CH＝CH2),6.34-6.20(m,1H,CH＝CH2),6.09(s,2H,OCH2O),5.88(br,1H,NH2),5.75-5.58(m,1H,CH＝CH2),4.97-4.75(m,1.5H,NCH 2CH),4.69-4.52(m,0.5H,NCH2CH),4.27-4.13(m,0.5H,NCH 2CH),4.10-3.94(m,0.5H,NCH 2CH),3.86-3.67(m,0.5H,NCH 2CH2),3.45-3.29(m,0.5H,NCH 2CH2),3.26-3.11(m,0.5H,NCH 2CH2),3.03-2.90(m,2H,CH 2CH2CH2CH 2),2.89-2.75(m,2.5H,NCH 2CH2,CH 2CH2CH2CH 2),2.46-2.31(m,1H,NCH2CHCH 2),2.30-2.20(m,1H,NCH2CHCH 2),2.10(br,1H,NH2),2.03-1.91(m,1H,NCH2CH 2),1.86-1.65(m,5H,CH2CH 2CH 2CH2,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C31H32N7O4:566.2516；Found:566.2512。
实施例21
(R)-N-(7-(7-(1-丙烯酰基哌啶-3-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅰ-21)的合成(R)-3-(4-氨基-5-碘-7H-吡咯并[2,3-d]嘧啶-7-基)哌啶-1-甲酸叔丁酯(Ⅲ-3)的合成
将5-碘-7H-吡咯并[2,3-d]嘧啶-4-胺(Ⅶ-2)(1.00g,3.85mmol)、(S)-1-叔丁氧羰基-3-羟基哌啶(Ⅷ-1)(1.55g,7.69mmol)、PPh3(2.02g,7.69mmol)、无水THF(100mL)加入250mL三颈瓶中，氮气保护，冰浴下搅拌30分钟，加入DIAD(1.56g,7.69mmol)，加毕，室温反应18小时。建议蒸去THF，加乙酸乙酯(100mL)溶解，依次用饱和碳酸钠(30mL×3)、水(30mL×3)和饱和氯化钠(30mL×3)洗涤，无水硫酸钠干燥。抽滤，滤液减压蒸除溶剂，残留物柱层析分离(洗脱剂:DCM:MeOH＝150～60:1)，得1.71g白色固体，产率70.6％，m.p.126-128℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.30(s,1H,ArH),7.16(s,1H,ArH),5.92(s,2H,NH2),4.82-4.66(m,1H,NCH 2CH),4.30-4.11(m,1H,NCH2CH),4.07-3.94(m,1H,NCH 2CH),3.35-3.19(m,1H,NCH 2CH2),3.10-2.93(m,1H,NCH 2CH2),2.24-2.12(m,1H,CHCH 2CH2),2.09-1.97(m,1H,CHCH 2CH2),1.91-1.79(m,1H,CHCH2CH 2),1.78-1.68(m,1H,CHCH2CH 2),1.49(s,9H,C(CH3)3)。
(R)-3-(5-(7-(1-萘甲酰胺)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)哌啶-1-甲酸叔丁酯(Ⅴ-21)的合成
以化合物Ⅲ-3(0.48g,1.08mmol)和Ⅳ-17(0.54g,1.30mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体353mg，产率53.7％，m.p.124-126℃。
(R)-N-(7-(4-氨基-7-(哌啶-3-基)-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅵ-21)的合成
以化合物Ⅴ-21(580mg,0.96mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体340mg，产率70.2％，不经进一步纯化，直接投下一步。
(R)-N-(7-(7-(1-丙烯酰基哌啶-3-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-1-萘甲酰胺(Ⅰ-21)的合成
以化合物Ⅵ-21(337mg,0.67mmol)和丙烯酰氯(65mg,0.70mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体189mg，产率50.7％，m.p.166-167.5℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.43(d,J＝7.41Hz,1H,ArH),8.31(s,1H,ArH),8.06-7.96(m,2H,ArH),7.94-7.84(m,2H,ArH),7.79(d,J＝6.51Hz,1H,ArH),7.65-7.46(m,3H,ArH,NH),7.16(s,1H,ArH),7.01(d,J＝8.49Hz,1H,ArH),6.70-6.54(m,1H,CH＝CH2),6.37-6.25(m,1H,CH＝CH2),6.05(s,2H,OCH2O),5.78-5.65(m,1H,CH＝CH2),5.40(s,1H,NH2),4.89-4.53(m,2H,NCH 2CH),4.39-4.23(m,0.5H,NCH 2CH),4.09-3.89(m,0.5H,NCH 2CH),3.44-3.14(m,1.5H,NCH 2CH2),2.96-2.77(m,0.5H,NCH 2CH2),2.34-2.24(m,1H,NCH2CHCH 2),2.22-2.09(m,2H,NCH2CHCH 2,NH2),2.02-1.88(m,1H,NCH2CH 2),1.82-1.65(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcdfor C32H29N6O4:561.2250；Found:561.2253。
实施例22
(R)-N-(7-(7-(1-丙烯酰基哌啶-3-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅰ-22)的合成(R)-3-(5-(7-(2-萘甲酰胺)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)哌啶-1-甲酸叔丁酯(Ⅴ-22)的合成
以化合物Ⅲ-3(1.00g,2.26mmol)和Ⅳ-18(1.13g,2.71mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体988mg，产率72.2％，m.p.124-126℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.43(s,1H,ArH),8.33(s,1H,ArH),8.09(s,1H,NH),8.03-7.86(m,5H,ArH),7.66-7.55(m,2H,ArH),7.19(s,1H,ArH),7.00(d,J＝8.91Hz,1H,ArH),6.10(s,2H,OCH2O),5.36(s,2H,NH2),4.84-4.67(m,1H,CHCH 2N),4.33-4.19(m,1H,CHCH2N),4.11-3.96(m,1H,CHCH 2N),3.31-3.16(m,1H,NCH 2CH2),3.02-2.85(m,1H,NCH 2CH2),2.33-2.15(m,2H,CHCH 2CH2),2.08-1.99(m,1H,CHCH2CH 2),1.87-1.78(m,1H,CHCH2CH 2),1.46(s,9H,C(CH3)3)。
(R)-N-(7-(4-氨基-7-(哌啶-3-基)-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅵ-22)的合成
以化合物Ⅴ-22(988mg,1.63mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体825mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(7-(1-丙烯酰基哌啶-3-基)-4-氨基-7H-吡咯并[2,3-d]嘧啶-5-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘甲酰胺(Ⅰ-22)的合成
以化合物Ⅵ-22(825mg,1.63mmol)和丙烯酰氯(155mg,1.71mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体356mg，产率38.9％，m.p.149.5-151℃。1H-NMR(400MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.32(s,1H,ArH),8.23(s,1H,NH),8.01-7.88(m,5H,ArH),7.68-7.53(m,2H,ArH),7.23-7.12(m,1H,ArH),6.99(s,1H,ArH),6.70-6.57(m,1H,CH＝CH2),6.38-6.27(m,1H,CH＝CH2),6.10(s,2H,OCH2O),5.78-5.66(m,1H,CH＝CH2),5.47(s,1H,NH2),4.91-4.67(m,1.5H,NCH 2CH),4.67-4.55(m,0.5H,NCH2CH),4.39-4.27(m,0.5H,NCH 2CH),4.08-3.94(m,0.5H,NCH 2CH),3.45-3.33(m,0.5H,NCH 2CH2),3.31-3.15(m,1H,NCH 2CH2),2.92-2.79(m,0.5H,NCH 2CH2),2.42-2.26(m,2H,NCH2CHCH 2,NH2),2.23-2.09(m,1H,NCH2CHCH 2),2.02-1.88(m,1H,NCH2CH 2),1.83-1.66(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C32H29N6O4:561.2250；Found:561.2254。
实施例23
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-苯基乙酰胺(Ⅰ-23)的合成
2-苯基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)乙酰胺(Ⅳ-23)的合成
将化合物Ⅺ(500mg,1.90mmol)、苯乙酸(388mg,2.85mmol)和1H-苯并三唑-1-基氧三吡咯烷基鏻六氟磷酸盐(PyBOP)(1.48g,2.84mmol)溶于DMF(6mL)中，加入DIEA(491mg,3.80mmol)，室温反应10小时。后处理方法同化合物IV-2，得白色固体215mg，产率29.7％，m.p.152-154℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.72(d,J＝8.10Hz,1H,ArH),7.45-7.29(m,5H,ArH),7.20(d,J＝8.46Hz,1H,ArH),7.14(s,1H,CONH),5.96(s,2H,OCH2O),3.76(s,2H,COCH2Ph),1.34(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(2-苯基乙酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-23)的合成
以化合物Ⅲ-1(0.20g,0.45mmol)和Ⅳ-23(0.21g,0.54mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体125mg，产率48.5％，m.p.130-132℃。1H-NMR(300MHz,CDCl3+D2O)δ(ppm):8.33(s,1H,ArH),7.83(d,J＝8.67Hz,1H,ArH),7.46-7.30(m,5H,ArH),7.05(d,J＝8.70Hz,1H,ArH),6.00(s,2H,OCH2O),4.90-4.75(m,1H,CHCH 2NBoc),4.38-4.21(m,1H,CHCH2NBoc),4.18-4.03(m,1H,CHCH 2NBoc),3.78(s,2H,COCH 2Ph),3.49-3.29(m,1H,NCH 2CH2),2.89-2.74(m,1H,NCH 2CH2),2.31-2.10(m,2H,NCH2CHCH 2),1.91-1.77(m,1H,NCH2CH 2),1.74-1.57(m,1H,NCH2CH 2),1.43(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-苯基乙酰胺(Ⅵ-23)的合成
以化合物Ⅴ-23(0.21g,0.37mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体136mg，产率78.51％。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-苯基乙酰胺(Ⅰ-23)的合成
以化合物Ⅵ-23(136mg,0.29mmol)和丙烯酰氯(31mg,0.34mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体61mg，产率40.4％，m.p.118-119.5℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.36(s,1H,ArH),7.87(d,J＝7.20Hz,1H,ArH),7.51-7.33(m,5H,ArH,NH),7.23(s,1H,NH),7.08(d,J＝8.46Hz,1H,ArH),6.70-6.52(m,1H,CH＝CH2),6.37-6.23(m,1H,CH＝CH2),6.03(s,2H,OCH2O),5.78-5.60(m,3H,CH＝CH2,NH2),4.94-4.82(m,1H,NCH 2CH),4.70-4.56(m,0.5H,NCH2CH),4.29-4.13(m,0.5H,NCH2CH),4.10-3.96(m,0.5H,NCH 2CH),3.88-3.73(m,2.5H,NCH 2CH,COCH 2Ph),3.46-3.30(m,0.5H,NCH 2CH2),2.96-2.81(m,0.5H,NCH 2CH2),2.50-2.35(m,1H,NCH 2CH2),2.32-2.25(m,1H,NCH2CHCH 2),2.08-1.94(m,1H,NCH2CHCH 2),1.93-1.87(m,1H,NCH2CH 2),1.76-1.66(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C28H28N7O4:526.2203；Found:526.2199.
实施例24
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-[1,1’-联苯]-4-甲酰胺(Ⅰ-24)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-[1,1’-联苯]-4-甲酰胺(Ⅳ-24)的合成
以化合物Ⅺ(1.00g,3.80mmol)和4-苯基苯甲酸(1.13g,5.70mmol)为原料，操作过程同化合物Ⅳ-2，得白色固体1.48g，产率88.1％，m.p.120-122℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.00-7.88(m,4H,ArH),7.72(d,J＝8.01Hz,2H,ArH),7.63(d,J＝6.96Hz,2H,ArH),7.52-7.45(m,2H,ArH,NH),7.43-7.40(m,1H,ArH),7.30(d,J＝8.64Hz,1H,ArH),6.09(s,2H,OCH2O),1.37(s,12H,4CH3)。
(R)-3-(3-(7-([1,1’-联苯]-4-基甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-24)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-24(0.96g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体821mg，产率71.9％，m.p.151-152℃。1H-NMR(300MHz,CDCl3+D2O)δ(ppm):8.36(s,1H,ArH),8.09-7.95(m,3H,ArH),7.79-7.72(m,2H,ArH),7.69-7.61(m,2H,ArH),7.54-7.38(m,3H,ArH),7.16(d,J＝8.16Hz,1H,ArH),6.15(s,2H,OCH2O),4.96-4.76(m,1H,CHCH 2NBoc),4.40-4.23(m,1H,CHCH2NBoc),4.19-4.08(m,1H,CHCH 2NBoc),3.59-3.25(m,1H,NCH 2CH2),2.96-2.74(m,1H,NCH 2CH2),2.38-2.15(m,2H,NCH2CHCH 2),1.94-1.86(m,1H,NCH2CH 2),1.79-1.62(m,1H,NCH2CH 2),1.45(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-[1,1’-联苯]-4-甲酰胺(Ⅵ-24)的合成
以化合物Ⅴ-24(750mg,1.18mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体468mg，产率74.1％，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-[1,1’-联苯]-4-甲酰胺(Ⅰ-24)的合成
以化合物Ⅵ-24(416mg,0.78mmol)和丙烯酰氯(74mg,0.82mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体212mg，产率46.3％，m.p.216-218℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.37(s,1H,ArH),8.14-7.94(m,4H,ArH,NH),7.74(d,J＝7.65Hz,2H,ArH),7.65(d,J＝7.65Hz,2H,ArH),7.56-7.37(m,3H,ArH),7.15(d,J＝8.67Hz,1H,ArH),6.69-6.51(m,1H,CH＝CH2),6.35-6.25(m,1H,CH＝CH2),6.15(s,2H,OCH2O),5.77(s,1H,NH2),5.73-5.63(m,1H,CH＝CH2),4.98-4.82(m,1.5H,NCH 2CH),4.70-4.58(m,0.5H,NCH2CH),4.27-4.16(m,0.5H,NCH 2CH),4.11-3.99(m,0.5H,NCH 2CH),3.85-3.73(m,0.5H,NCH 2CH2),3.47-3.35(m,0.5H,NCH2CH2),3.26-3.14(m,0.5H,NCH 2CH2),2.94-2.80(m,0.5H,NCH 2CH2),2.49-2.34(m,1H,NCH2CHCH2),2.31-2.21(m,1H,NCH2CHCH 2),2.07-1.94(m,1H,NCH2CH 2),1.88(s,1H,NH2),1.78-1.65(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C33H30N7O4:588.2359；Found:588.2359。
实施例25
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯磺酰胺(Ⅰ-25)的合成
4-甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯磺酰胺(Ⅳ-25)的合成
将Ⅺ(1.00g,3.80mmol)、吡啶(1.50g,19.00mmol)和二氯甲烷(20mL)混合，冰浴搅拌下，滴加4-甲氧基苯磺酰氯(0.94g,4.56mmol)的二氯甲烷溶液，滴毕，室温反应8.5小时。后处理方法同化合物IV-1，得淡黄色固体985mg，产率59.7％，m.p.186-188℃。1H-NMR(300MHz,CDCl3)δ(ppm):7.74(d,J＝8.67Hz,2H,ArH),7.15(d,J＝8.37Hz,1H,ArH),7.02(d,J＝8.28Hz,1H,ArH),6.88(d,J＝8.55Hz,2H,ArH),6.56(s,1H,NH),5.88(s,2H,OCH2O),3.83(s,3H,OCH3),1.33(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(4-甲氧基苯磺酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-25)的合成
以化合物Ⅲ-1(0.46g,1.04mmol)和Ⅳ-25(0.54g,1.24mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体592mg，产率91.5％，m.p.182-184℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.34(s,1H,ArH),7.80(d,J＝8.85Hz,2H,ArH),7.26(s,1H,NH),7.19(d,J＝8.70Hz,1H,ArH),7.03(d,J＝8.70Hz,1H,ArH),6.94(d,J＝8.88Hz,2H,ArH),5.95(s,2H,OCH2O),5.69(s,2H,NH2),4.89-4.77(m,1H,CHCH 2NBoc),4.37-4.23(m,1H,CHCH2NBoc),4.19-4.08(m,1H,CHCH 2NBoc),3.86(s,3H,OMe),3.47-3.33(m,1H,NCH 2CH2),2.89-2.77(m,1H,NCH 2CH2),2.27-2.11(m,2H,NCH2CHCH 2),1.94-1.81(m,2H,NCH2CH 2),1.44(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯磺酰胺(Ⅵ-25)的合成
以化合物Ⅴ-25(500mg,0.80mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色油状物741mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-甲氧基苯磺酰胺(Ⅰ-25)的合成
以化合物Ⅵ-25(500mg,0.96mmol)和丙稀酸(91mg,1.00mmol)为原料，操作过程同化合物Ⅰ-4，得白色固体287mg，产率52.0％，m.p.157.5-159.0℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.32(s,1H,ArH),7.80(d,J＝8.52Hz,2H,ArH),7.18(d,J＝8.88Hz,1H,ArH),7.02(d,J＝8.61Hz,1H,ArH),6.94(d,J＝8.67Hz,2H,ArH),6.68-6.49(m,1H,CH＝CH2),6.34-6.21(m,1H,CH＝CH2),5.95(s,2H,OCH2O),5.86(s,1H,NH2),5.75-5.60(m,1H,CH＝CH2),4.96-4.77(m,1.5H,NCH 2CH),4.66-4.53(m,0.5H,NCH2CH),4.23-4.12(m,0.5H,NCH 2CH),4.08-3.97(m,0.5H,NCH 2CH),3.86(s,3H,OCH3),3.53-3.43(m,0.5H,NCH 2CH2),3.39-3.27(m,0.5H,NCH 2CH2),3.24-3.10(m,0.5H,NCH 2CH2),2.97-2.78(m,0.5H,NCH 2CH2),2.46-2.19(m,2H,NCH2CHCH 2,NH2),2.11-1.91(m,2H,NCH2CHCH 2CH 2),1.81-1.64(m,1H,NCH2CHCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C27H28N7O6S:578.1822；Found:578.1819。
实施例26
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘磺酰胺(Ⅰ-26)的合成
N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)萘-2-磺酰胺(Ⅳ-26)的合成
以化合物Ⅺ(1.00g,3.80mmol)和2-萘磺酰氯(1.29g,5.70mmol)为原料，操作过程同化合物Ⅳ-25，得白色固体1.02g，产率59.2％，m.p.180-182℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.41(s,1H,ArH),7.94-7.84(m,3H,ArH),7.81(d,J＝8.76Hz,1H,ArH),7.66-7.54(m,2H,ArH),7.16-7.07(m,2H,ArH),6.76(s,1H,NHCO),5.80(s,2H,OCH2O),1.30(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(2-萘磺酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-26)的合成
以化合物Ⅲ-1(0.80g,1.80mmol)和Ⅳ-26(0.98g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体718mg，产率61.9％，m.p.172-174℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.32(s,1H,ArH),7.99-7.80(m,4H,ArH),7.70-7.57(m,2H,ArH),7.50(s,1H,NH),7.30-7.23(m,1H,ArH),7.03(d,J＝8.46Hz,1H,ArH),5.85(s,2H,OCH2O),5.66(s,2H,NH2),4.88-4.73(m,1H,CHCH 2NBoc),4.36-4.19(m,1H,CHCH2NBoc),4.17-4.03(m,1H,CHCH 2NBoc),3.43-3.28(m,1H,NCH 2CH2),2.88-2.73(m,1H,NCH 2CH2),2.25-2.08(m,2H,NCH2CHCH 2),1.91-1.79(m,1H,NCH2CH 2),1.73-1.60(m,1H,NCH2CH 2),1.42(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘磺酰胺(Ⅵ-26)的合成
以化合物Ⅴ-26(907mg,1.41mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体588mg，产率76.7％，不经进一步纯化,直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-2-萘磺酰胺(Ⅰ-26)的合成
以化合物Ⅵ-26(500mg,0.92mmol)和丙烯酰氯(87mg,0.80mmol)为原料，操作过程同目标化合物Ⅰ-1，得白色固体134mg，产率24.3％，m.p.166.5-167℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.44(s,1H,ArH),8.30(d,J＝8.85Hz,1H,ArH),8.02-7.80(m,4H,ArH),7.71-7.54(m,2H,ArH),7.21(d,J＝8.13Hz,1H,ArH),7.00(d,J＝7.95Hz,1H,ArH),6.70-6.46(m,1H,CH＝CH2),6.38-6.19(m,1H,CH＝CH2),6.03-5.77(m,3H,NH2,OCH2O),5.75-5.59(m,1H,CH＝CH2),4.92-4.74(m,1.5H,NCH 2CH),4.67-4.52(m,0.5H,NCH2CH),4.23-4.09(m,0.5H,NCH 2CH),4.08-3.95(m,0.5H,NCH 2CH),3.78-3.63(m,0.5H,NCH 2CH2),3.38-3.23(m,0.5H,NCH 2CH2),3.21-3.09(m,0.5H,NCH 2CH2),2.91-2.76(m,0.5H,NCH 2CH2),2.45-2.08(m,3H,NCH2CHCH 2,NH2),2.03-1.88(m,1H,NCH2CH 2),1.78-1.52(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C30H28N7O5S:598.1873；Found:598.1873。
实施例27
(R)-N-(7-(4-氨基-1-(1-(2-氰基-3-环丙基丙烯酰基)哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅰ-27)的合成
(R)-N-(7-(4-氨基-1-(1-(2-氰基乙酰基)哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅻ-27)的合成
将化合物Ⅵ-1(300mg,0.66mmol)、氰乙酸(67mg,0.79mmol)、HOBt(133mg,0.98mmol)、EDCI(189mg,0.98mmol)和TEA(133mg,1.31mmol)溶于6mL DMF中，室温搅拌12小时。后处理方法同化合物I-4，得白色固体210mg，产率61.1％，m.p.167.5-169.5℃。1H-NMR(300MHz,DMSO-d6)δ(ppm):10.25(s,1H,NH),8.24(d,J＝6.09Hz,1H,ArH),7.99(d,J＝7.95Hz,2H,ArH),7.68-7.49(m,3H,ArH),7.20(d,J＝7.95Hz,1H,ArH),7.10-6.99(m,1H,ArH),6.15(s,2H,OCH2O),4.92-4.80(m,0.5H,NCH 2CH),4.77-4.64(m,0.5H,NCH 2CH),4.48-4.38(m,0.5H,NCH2CH),4.16-4.06(m,2H,CNCH 2CO),4.05-3.99(m,0.5H,NCH2CH),3.97-3.85(m,0.5H,NCH 2CH),3.80-3.64(m,1H,NCH 2CH,NCH 2CH2),3.27-3.13(m,1H,NCH 2CH2),3.06-2.95(m,0.5H,NCH 2CH2),2.25-2.03(m,2H,NCH2CHCH 2),1.94-1.54(m,2H,NCH2CH 2)。
(R)-N-(7-(4-氨基-1-(1-(2-氰基-3-环丙基丙烯酰基)哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)苯甲酰胺(Ⅰ-27)的合成
将Ⅻ-27(100mg,0.19mmol)、甲醇(3mL)、哌啶(24mg,0.29mmol)和环丙甲醛(20mg,0.29mmol)混合，室温反应2小时。减压浓缩，用乙酸乙酯溶解，依次用水(10mL×3)、饱和氯化钠(10mL×3)洗涤，减压浓缩得粗品，柱层析(洗脱剂:二氯甲烷:甲醇＝100～60:1)分离得68mg白色固体，产率61.8％，m.p.155.5-157℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.37(s,1H,ArH),8.07(s,1H,NH),8.03-7.92(m,3H,ArH),7.67-7.50(m,3H,ArH),7.16(d,J＝8.61Hz,1H,ArH),6.70-6.49(m,1H,CH＝CH2),6.15(s,2H,OCH2O),5.97(s,2H,NH2),5.04-4.89(m,1H,NCH 2CH),4.69-4.47(m,0.5H,NCH2CH),4.37-4.18(m,1H,NCH 2CH),3.74-3.48(m,0.5H,NCH 2CH),3.41-3.06(m,1H,NCH 2CH2),2.52-2.38(m,1H,NCH 2CH2),2.35-2.24(m,1H,CHCH 2CH2),2.23-2.12(m,2H,CHCH 2CH 2),2.11-1.99(m,2H,CHCH2CH 2,C＝CCH),1.93-1.74(m,1H,C＝CCHCH 2CH2),1.39-1.13(m,3H,C＝CCHCH 2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd forC31H29N8O4:577.2312；Found:577.2318。
实施例28
(S)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-(二甲基氨基)苯甲酰胺(Ⅰ-28)的合成
以(R)-1-叔丁氧羰基-3-羟基哌啶(Ⅷ-3)替换化合物VIII-1，实验操作参照化合物I-1或I-13的制备，得白色固体I-28，m.p.160-162℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.32(s,1H,ArH),8.00(d,J＝8.88Hz,1H,ArH),7.86(s,1H,NH),7.81(d,J＝8.04Hz,2H,ArH),7.10(d,J＝8.73Hz,1H,ArH),6.71(d,J＝8.49Hz,2H,ArH),6.66-6.52(m,1H,CH＝CH2),6.35-6.22(m,2H,CH＝CH2,NH2),6.11(s,2H,OCH2O),5.75-5.61(m,1H,CH＝CH2),4.97-4.80(m,1.5H,NCH 2CH),4.70-4.54(m,0.5H,NCH2CH),4.30-4.14(m,0.5H,NCH 2CH),4.09-3.95(m,0.5H,NCH 2CH),3.86-3.69(m,0.5H,NCH 2CH2),3.46-3.31(m,0.5H,NCH 2CH2),3.25-3.13(m,0.5H,NCH 2CH2),3.06(s,6H,N(CH3)2),2.92-2.79(m,1.5H,NCH 2CH2,NH2),2.47-2.35(m,1H,NCH2CHCH 2),2.30-2.17(m,1H,NCH2CHCH 2),2.08-1.91(m,1H,NCH2CH 2),1.82-1.64(m,1H,NCH2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H31N8O4:555.2468；Found:555.2471。
实施例29
(S)-N-(7-(1-((1-丙烯酰基吡咯烷-2-基)甲基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-二甲氨基苯甲酰胺(Ⅰ-29)的合成(S)-2-((4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)吡咯烷-1-甲酸叔丁酯(Ⅲ-5)的合成
将化合物Ⅶ-1(1.50g,5.75mmol)、Boc-L-脯氨醇(Ⅷ-4)(2.31g,11.49mmol)、PPh3(3.01g,11.49mmol)和无水THF(100mL)混合，氮气保护，冰浴下搅拌30分钟，加入DIAD(2.32g,11.49mmol)，加毕，室温反应18小时。后处理方法同化合物III-1，得1.48g淡黄色固体，产率58.0％，m.p.176-178℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.36(s,1H,ArH),6.24(s,2H,NH2),4.65-4.27(m,3H,NCH 2CHNBoc),3.51-3.26(m,2H,CH2CH2CH 2NBoc),2.00-1.77(m,4H,CH 2CH 2CH2NBoc),1.48(s,9H,3CH3).
(S)-2-((4-氨基-3-(7-(4-(二甲基氨基)苯甲酰氨基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)吡咯烷-1-甲酸叔丁酯(Ⅴ-29)的合成
以化合物Ⅲ-5(0.80g,1.80mmol)和Ⅳ-13(0.89g,2.16mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体820mg，产率75.8％，m.p.138-140℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.38(s,1H,ArH),8.06(d,J＝8.64Hz,1H,ArH),7.91-7.82(m,3H,ArH,NHCO),7.17(d,J＝8.73Hz,1H,ArH),6.76(d,J＝8.70Hz,2H,ArH),6.15(s,2H,OCH2O),5.95(br,2H,NH2),4.72-4.59(m,1H,NCH 2CHNBoc),4.46-4.35(m,1H,NCH 2CHNBoc),3.50-3.38(m,1H,NCH2CHNBoc),3.35-3.24(m,1H,CH2CH2CH 2NBoc),3.11(s,6H,N(CH3)2),3.07-3.03(m,1H,CH2CH2CH 2NBoc),2.01-1.78(m,4H,CH 2CH 2CH2NBoc),1.48(s,9H,3CH3)。
(S)-N-(7-(4-氨基-1-(吡咯烷-2-基甲基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-二甲氨基苯甲酰胺(Ⅵ-29)的合成
以化合物Ⅴ-29(650mg,1.08mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体443mg，产率81.8％，不经进一步纯化,直接投下一步。
(S)-N-(7-(1-((1-丙烯酰基吡咯烷-2-基)甲基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-二甲氨基苯甲酰胺(Ⅰ-29)的合成
以化合物Ⅵ-29(360mg,0.72mmol)和丙烯酰氯(68mg,0.76mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体168mg，产率42.1％，m.p.98-100℃。1H-NMR(300MHz,CDCl3+D2O)δ(ppm):8.28(d,J＝8.19Hz,1H,ArH),7.89-7.72(m,3H,ArH),7.01(d,J＝8.52Hz,1H,ArH),6.64(d,J＝8.52Hz,2H,ArH),6.42-6.31(m,1H,CH＝CH2),6.28-6.16(m,1H,CH＝CH2),6.09-5.97(m,2H,OCH2O),5.71-5.45(m,1H,CH＝CH2),4.85-4.26(m,5H,NCH 2CHN,NH2),3.70-3.52(m,1H,NCH 2CH2),3.48-3.37(m,1H,NCH 2CH2),3.00(s,6H,2CH3),2.11-1.53(m,4H,NCH2CH 2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H31N8O4:555.2468；Found:555.2471。
实施例30
(R)-N-(7-(1-((1-丙烯酰基吡咯烷-2-基)甲基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-4-二甲氨基苯甲酰胺(Ⅰ-30)的合成
以Boc-D-脯氨醇(VIII-5)替换化合物Ⅷ-4，实验操作参照化合物I-29的制备，得白色固体157mg，产率30.7％，m.p.98-100℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.37(d,J＝7.65Hz,1H,ArH),8.05-7.94(m,2H,ArH,NHCO),7.85(d,J＝8.70Hz,2H,ArH),7.11(d,J＝8.61Hz,1H,ArH),6.74(d,J＝8.79Hz,2H,ArH),6.48-6.41(m,1H,CH＝CH2),6.38-6.27(m,1H,CH＝CH2),6.18-6.10(m,3H,NH2,OCH2O),5.76-5.58(m,1H,CH＝CH2),4.81-4.36(m,3H,NCH 2CHN),3.82-3.61(m,1H,NCH 2CH2),3.56-3.45(m,1H,NCH 2CH2),3.09(s,6H,2CH3),2.73(s,1H,NH2),2.19-1.79(m,4H,NCH2CH 2CH 2)；HRMS(ESI):m/z[M+H]+.Calcd for C29H31N8O4:555.2468；Found:555.2470。
实施例31
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)--5-氟苯并呋喃-2-甲酰胺(Ⅰ-31)合成
4-甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5-氟苯并[b]呋喃-2-甲酰胺(Ⅳ-31)的合成
以Ⅺ(321m g,0.12mol)、5-氟苯并[b]呋喃-2甲酸(200mg,0.11mol)为原料，操作过程同化合物Ⅳ-2,得黄色固体407mg，产率87.01％，m.p.92.0-94.0℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.39(s,1H,NHCO),7.94(d,J＝8.49Hz,1H,ArH),7.62(s,1H,ArH),7.56(dd,J＝9.06Hz,1H,ArH),7.41(dd,J＝8.16Hz,1H,ArH),7.34(d,J＝8.49Hz,1H,ArH),7.24(td,J＝9.00Hz,1H,ArH),6.18(s,2H,OCH2O),1.42(s,12H,4CH3)。
(R)-3-(4-氨基-3-(7-(5-氟苯并[b]呋喃-2-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-31)的合成
以化合物Ⅲ-1(345mg,0.78mmol)和Ⅳ-31(300mg,0.7mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体314mg，产率72.86％，m.p.204-206℃。1H-NMR(300MHz,CDCl3)δ(ppm):8.40(s,1H,NHCO),8.39(s,1H,ArH),8.05(d,J＝8.7Hz,1H,ArH),7.63(s,1H,ArH),7.56(dd,J＝9.56Hz,1H,ArH),7.40(dd,J＝8.13Hz,1H,ArH),7.23(td,J＝9.00Hz,1H,ArH),7.17(d,J＝8.73Hz,1H,ArH),6.20(s,2H,OCH2O),5.76(s,2H,NH2),4.98-4.80(m,1H,CHCH 2NBoc),4.50-4.25(m,1H,CHCH2NBoc),4.25-4.10(m,1H,CHCH 2NBoc),3.50-3.32(m,1H,NCH 2CH2),2.95-2.80(m,1H,NCH2 CH2),2.38-2.26(m,1H,NCH2CHCH 2),2.25-2.17(m,1.0H,NCH2CHCH 2,NCH2CH 2),1.81-1.72(m,1.0H,NCH2CH 2),1.47(s,9H,NBoc)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5-氟苯并[b]呋喃-2-甲酰胺(Ⅵ-31)的合成
以化合物Ⅴ-31(300mg,0.49mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体206mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-5-氟苯并[b]呋喃-2-甲酰胺(Ⅰ-31)的合成
以化合物Ⅵ-31(200mg,0.39mmol)和丙稀酰氯(37mg,0.4mmol)为原料，操作过程同化合物Ⅰ-1，得白色固体72mg，产率32.3％，m.p.184.0-186.0℃。1H-NMR(300MHz,CDCl3)δ(ppm):10.55(s,1H,NHCO),8.26(s,1H,ArH),7.84(s,1H,ArH),7.80(q,J＝9.27Hz,1H,ArH),7.69(q,J＝8.64Hz,1H,ArH),7.40(td,J＝9.21Hz,1H,ArH),7.25(d,J＝8.64Hz,1H,ArH),7.08(d,J＝8.49Hz,1H,ArH),6.95-6.70(m,1H,CH＝CH2),6.20(s,2H,OCH2O),6.15-6.04(m,1H,CH＝CH2 ),5.86(s,2H,NH2),5.78-5.60(m,1H,CH＝CH 2),4.79-4.65(m,1H,CHCH 2NBoc),4.63-4.51(m,0.5H,CHCH2NBoc),4.35-4.20(m,1H,CHCH 2NBoc),4.18-4.04(m,1H,NCH 2CH),3.81-3.65(m,0.5H,CHCH2NBoc),3.29-3.22(m,1H,NCH 2CH2),2.37-2.23(m,1H,NCH2CHCH 2),2.20-2.10(m,1H,NCH2CHCH 2),2.00-1.90(m,1H,NCH2CH 2)，1.72-1.53(m,1H,NCH2CH 2)。
实施例32
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-苯并[b]噻吩-2-甲酰胺(Ⅰ-32)合成
4-甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-苯并[b]噻吩-2-甲酰胺(Ⅳ-32)的合成
以Ⅺ(2.28g,0.018mol)、苯并[b]噻吩-2甲酸(1.63g,0.0091mol)为原料，操作过程同化合物Ⅳ-2,得黄色固体2.78g，产率72.09％，m.p.124-125℃。1H-NMR(300MHz,CDCl3):δ(ppm):10.56(s,1H,NHCO),8.39(s,1H,ArH),8.08(d,J＝7.08Hz,1H,ArH),8.03(d,1H,J＝6.66Hz),7.58-7.46(m,2H,ArH),7.09(m,2H,ArH),6.12(s,2H,OCH2O),1.32(s,12H,CH3)。
(R)-3-(4-氨基-3-(7-(苯并[b]噻吩-2-甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-32)的合成
以化合物Ⅲ-1(1.4g,3.1mmol)和Ⅳ-32(1.2g,2.8mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体834mg，产率48.53％，m.p.126.0-128.0℃。1H-NMR(300MHz,CDCl3),δ(ppm):8.42(s,1H,NHCO),8.03(d,1H,J＝8.82Hz,ArH),8.00(s,1H,ArH),7.99-7.92(m,3H,ArH),7.58-7.44(m,2H,ArH),7.20(d,1H,J＝8.70Hz,ArH),6.20(s,2H,OCH2O),5.80(s,2H,NH2),4.90(m,1H,CHCH 2NBoc),4.52-4.28(m,1H,CHCH2NBoc),4.27-4.13(m,1H,CHCH 2NBoc),3.62-3.33(m,1H,NCH 2CH2),2.88(m,1H,NCH 2CH2),2.40-2.28(m,1H,NCH2CHCH 2),2.28-2.22(m,1H,NCH2CHCH 2),1.83-1.74(m,1H,NCH2CH 2),1.74-1.65(1H,NCH2CH 2),1.51(s,9H,CH3)。
(R)-N-(7-(4-氨基-1-(哌啶-3-基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-苯并[b]噻吩-2-甲酰胺(Ⅵ-32)的合成
以化合物Ⅴ-32(0.8g,1.3mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体301mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-苯并[b]噻吩-2-甲酰胺(Ⅰ-32)的合成
以化合物Ⅵ-32(300mg,0.58mmol)和丙稀酰氯(63mg,0.696mmol)为原料，操作过程同化合物Ⅰ-4，得白色固体79mg，产率24.01％，m.p.162.0-164.0℃。
1H-NMR(300MHz,CDCl3):δ(ppm):1H-NMR(300MHz,CDCl3),δ(ppm):8.42(s,1H,NHCO),8.03(d,1H,J＝8.91Hz,ArH),8.01(s,1H,ArH),7.98(d,2H,J＝3.57Hz,ArH),7.95(s,1H,ArH),7.52(m,2H,ArH),7.19(d,J＝8.64Hz,1H,ArH),6.75-6.60(m,1H,CH＝CH2),6.42-6.30(m,1H,CH＝CH 2),6.21(s,2H,OCH2O),5.85-5.7(m,3H,CH＝CH 2,NH2),5.01-4.87(m,1.5H,CHCH 2NBoc,CHCH2NBoc),4.76-4.63(m,0.5H,CHCH2NBoc),4.32-4.22(m,0.5H,CHCH 2NBoc),4.15-4.04(m,0.5H,CHCH 2NBoc),3.89-3.77(m,0.5H,NCH 2CH2),3.75-3.52(m,0.5H,NCH 2CH2),3.49-3.37(m,0.5H,NCH 2CH2),3.32-3.18(m,0.5H,NCH 2CH2),2.99-2.83(m,1H,NCH2CHCH 2),2.51-2.38(m,1H,NCH2CHCH 2),2.37-2.21(m,1H,NCH2CH 2),2.11-1.99(m,1H,NCH2CH 2)。
实施例33
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-(4-甲基哌嗪-1-基)苯甲酰胺(Ⅰ-33)合成
4-甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-(4-甲基哌嗪-1-基)苯甲酰胺(Ⅳ-33)的合成
以Ⅺ(1.43g,0.0055mol)、3-(4-甲基哌嗪-1-基)苯甲酸(1.00g,0.0045mol)为原料，操作过程同化合物Ⅳ-2,得白色固体1.80g，产率85.98％，m.p.142.0-144.0℃。1H-NMR(300MHz,DMSO):δ(ppm):10.20(s,1H,NHCO),8.41(s,1H,ArH),7.67(d,J＝7.95Hz,1H,ArH),7.52(d,J＝8.46Hz,1H,ArH),7.36-7.30(m,1H,ArH),7.24(s,1H,ArH),7.12(t,J＝7.34Hz,1H,ArH),6.12(s,2H,OCH2O),3.99(s,3H,NCH3),1.32(s,12H,CH3)。
(R)-3-(4-氨基-3-(7-(4-甲基哌嗪-苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-33)的合成
以化合物Ⅲ-1(0.178g,4mmol)和Ⅳ-33(0.17g,37mmol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体98mg，产率40.42％，m.p.182-184℃。1H-NMR(300MHz,DMSO),δ(ppm):9.56(s,1H,NHCO),8.41(s,1H,ArH),8.02(d,J＝8.7Hz,1H,ArH),7.93(s,1H,ArH),7.52-7.47(m,1H,ArH),7.35(s,1H,ArH),7.18(d,J＝8.64,1H,ArH),7.13-7.17(m,1H,ArH),6.16(s,2H,OCH2O),5.78(s,2H,NH2),4.96-4.83(m,1H,CH 2CHNBoc),4.47-4.27(m,1H,CH2CHNBoc),4.26-4.17(m,1H,CH 2CHNBoc),3.41-3.35(m,4H,CH2NCH2),3.25-3.19(m,4H,CH 2N(CH3)CH2),2.95-2.81(m,1H,NCH 2CH2),2.49(s,3H,NCH3),2.40-2.29(m,1H,NCH 2CH2),2.28-2.19(m,1.5H,NCH2CHCH 2,NCH2CH 2),1.79-1.69(m,1.5H,NCH2CH 2),1.49(s,9H,Boc)。
以化合物Ⅴ-33(98mg,17mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体80mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-吗啉苯甲酰胺(Ⅰ-33)的合成
以化合物Ⅵ-33(80mg,0.14mmol)和丙稀酰氯(15mg,0.16mmol)为原料，操作过程同化合物Ⅰ-4，得白色固体49mg，产率55.85％，m.p.152.0-154.0℃。1H-NMR(300MHz,DMSO),δ(ppm):10.23(s,1H,NHCO),8.41(s,1H,ArH),8.04(d,J＝8.7Hz,1H,ArH),7.52-7.47(m,1H,ArH),7.33(d,J＝7.08Hz,1H,ArH),7.18(d,1H,J＝8.7Hz,ArH),7.16(s,1H,ArH),7.12-7.07(m,1H,ArH),6.71-6.58(m,1H,CH＝CH2),6.39-6.29(m,1H,CH＝CH 2),6.16(s,2H,OCH2O),5.80-5.66(m,3H,NH2,CH＝CH 2),4.99-4.85(m,1.5H,CH 2CHNBoc,CH2CHNBoc),4.72-4.62(m,0.5H,CH2CHNBoc),4.30-4.20(m,0.5H,CH 2CHNBoc),4.15-4.02(m,0.5H,CH 2CHNBoc),3.86-3.73(m,0.5H,NCH 2CH2),3.41-3.36(m,4H,CH2NCH2),3.25-3.19(m,4H,CH2N(CH3)CH2),2.97-2.84(m,0.5H,NCH 2CH2),2.49(s,3H,CH3),2.45-2.36(m,1H,NCH 2CH2),2.35-2.26(m,1H,CH 2CHNBoc),2.08-1.99(m,1H,NCH 2CHCH2),1.79-1.70(m,2H,NCH 2CHCH2)。
实施例34
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-吗啉苯甲酰胺(Ⅰ-34)合成
4-甲氧基-N-(7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-吗啉苯甲酰胺(Ⅳ-34)的合成
以Ⅺ(0.65g,0.0025mol)、3-(4-甲基哌嗪-1-基)苯甲酸(0.5g,0.0023mol)为原料，操作过程同化合物Ⅳ-2,得白色固体732mg，产率73.32％，m.p.192-194℃。1H-NMR(300MHz,DMSO):δ(ppm):10.21(s,1H,NHCO),7.92(s,1H,ArH),7.89(d,J＝8.31Hz,1H,ArH),7.56(d,J＝6.69Hz,1H,ArH),7.50(t,J＝7.77Hz,1H,ArH),7.09(d,J＝7.86Hz,1H,ArH),7.04(d,J＝8.31Hz,1H,ArH),6.09(s,2H,OCH2O),5.73(s,2H,NH2),3.66-3.60(m,4H,CH2NCH 2),3.56(s,2H,CH2),2.46-2.36(m,4H,CH2OCH2),1.32(s,12H,CH3)。
(R)-3-(4-氨基-3-(7-(3-吗啉苯甲酰胺基)苯并[d][1,3]二氧杂环戊烯-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(Ⅴ-34)的合成
以化合物Ⅲ-1(0.77g,0.0017mol)和Ⅳ-34(0.7g,0.0016mol)为原料，操作过程同化合物Ⅴ-1，得淡黄色固体546mg，产率51.99％，m.p.182-184℃。1H-NMR(300MHz,DMSO),δ(ppm):10.28(s,1H,NHCO),8.27(s,1H,ArH),8.03-7.86(m,2H,ArH),7.69-7.46(m,2H,ArH),7.22(d,J＝7.95Hz,1H,ArH),7.07(d,J＝7.62Hz,1H,ArH),6.98-6.73(m,1H,CH＝CH2),6.28-6.02(m,3H,OCH2O,CH＝CH 2),5.75(s,2H,NH2)5.85-5.58(m,1H,CH＝CH 2),4.83-4.66(m,1H,CH 2CHNBoc),4.54-4.65(m,0.5H,CH2CHNBoc),4.38-4.20(m,1H,CH 2CHNBoc),4.20-4.02(m,0.5H,CH2CHNBoc),3.82-3.70(m,0.5H,NCH 2CH2),3.71-3.53(m,4H,CH2NCH2),3.59(s,2H,CH2),3.31-3.16(m,1H,NCH 2CH2),3.09-2.92(m,0.5H,NCH 2CH2)2.50-2.42(m,4H,CH2OCH2),2.35-2.23(m,1H,NCH2CHCH 2)2.22-2.19(m,1H,NCH2CHCH 2),2.06-1.90(m,1H,NCH2CH 2),1.75-1.54(m,1H,NCH2CH 2),1.42(s,9H,Boc)。
以化合物Ⅴ-34(0.54g,082mmol)为原料，操作过程同化合物Ⅵ-1，得淡黄色固体472mg，不经进一步纯化，直接投下一步。
(R)-N-(7-(1-(1-丙烯酰基哌啶-3-基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-3-基)苯并[d][1,3]二氧杂环戊烯-4-基)-3-吗啉苯甲酰胺(Ⅰ-34)的合成
以化合物Ⅵ-34(400mg,0.72mmol)和丙稀酰氯(72mg,0.79mmol)为原料，操作过程同化合物Ⅰ-4，得白色固体225mg，产率46.67％，m.p.148.0-150.0℃。1H-NMR(300MHz,DMSO),δ(ppm):10.25(s,1H,NHCO),8.24(s,1H,ArH),7.93(s,1H,ArH),7.92-7.87(m,1H,ArH)7.57-7.53(m,1H,ArH),7.50(t,J＝7.44Hz,1H,ArH),7.18(d,J＝8.58Hz,1H,ArH),7.05(d,J＝8.55Hz,1H,ArH),6.93-6.71(m,1H,CH＝CH2),6.14(s,2H,OCH2O),6.13-6.03(m,1H,CH＝CH 2),5.78(s,2H,NH2),5.75-5.59(m,1H,CH＝CH 2),4.78-4.65(m,1H,CH 2CHNBoc),4.62-4.53(m,0.5H,CH2CHNBoc),4.31-4.18(m,1H,CH 2CHNBoc),4.15-4.08(m,0.5H,CH2CHNBoc),3.74-3.64(m,1H,NCH 2CH2),3.63-3.58(m,4H,CH 2NCH 2),3.57-3.54(s,2H,CH2),3.27-3.20(m,1H,NCH 2CH2),2.45-2.35(m,4H,CH 2OCH 2),2.31-2.21(m,1H,NCH2CHCH 2),2.17-2.08(m,1H,NCH2CHCH 2),1.98-1.88(m,1H,NCH2CH 2),1.69-1.52(m,1H,NCH2CH 2)
实施例35
上述制备所得部分化合物的药理学实验及结果如下：
1.BTK、JAK3激酶抑制活性实验
实验方法：384孔反应板分为化合物孔(10μM起始，3倍稀释共10个浓度)、阳性对照孔和阴性对照孔，化合物孔和阳性对照孔加入激酶溶液，阴性对照孔加入1×kinasebuffer，离心30秒后室温孵育10min。加入15μL的ATP和底物的混合溶液，离心后震荡混匀室温孵育(JAK3孵育30分钟，BTK孵育20分钟)。加入终止检测液停止反应，用Caliper EZreader读取转化率。
数据分析：计算公式
其中：Conversion％_sample是样品的转化率读数；Conversion％_min是阴性对照孔均值，代表没加酶孔的转化率读数；Conversion％_max是阳性对照比值孔均值，代表没加化合物孔的转化率读数。
拟合量效曲线：以浓度的log值作为X轴，百分比抑制率为Y轴，采用分析软件GraphPad Prism 5的log(inhibitor)vs.response-Variable slope拟合量效曲线，从而得出各个化合物对酶活性的IC50值。
实验结果：对本发明部分化合物进行体外BTK、JAK3激酶抑制活性的筛选，结果见表1。
注：A:IC50:0.001～0.05μM；B:IC50:0.05～0.5μM；C:IC50:>0.5μM。
表1.部分化合物对BTK、JAK3激酶的抑制活性
/>
表1结果显示，本发明化合物对BTK、JAK3激酶均有较好的抑制活性，其中化合物I-6、I-7、I-10、I-11、I-13～I-22、I-32对BTK和JAK3呈现出良好的抑制活性。
2.化合物对BaF3-TEL-JAK3和Daudi细胞的增殖抑制作用
实验过程：将处于对数生长期的细胞以一定数量接种于96孔板37℃培养后加药。药物作用72h后，将96孔细胞板平衡至室温后，每孔加40uL Cell 试剂，振摇2分钟静置10分钟；用MD SpectraMax Paradigm酶标仪检测化学发光信号。
数据分析：计算公式
Max signal:DMSO信号；Min signal:介质信号。
使用GraphPad Prism 5计算IC50。
注：A:IC50:0.01～0.5μM,B:IC50:0.5～1μM,C:IC50:>1μM。
表2.部分化合物对BaF3-JAK3和Daudi细胞的增殖抑制活性
/>
实验结果显示，受试化合物对BaF3-JAK3的细胞增殖抑制活性明显优于依鲁替尼；受试化合物对BTK高表达的Daudi细胞表现出较好的增殖抑制能力，部分受试化合物对Daudi细胞的增值抑制活性优于依鲁替尼。
Claims (7)
1.通式(I)的化合物或其药学上可接受的盐：
其中：X代表N或CH；A代表-NHCO-；m代表0，n代表1；
R1代表 其中R7代表H、F、Cl、CH3、t-Bu、CF3、OCH3、N(CH3)2、N(C2H5)2、CONHCH2CF3，R7为单取代或双取代，R8代表CH3。
R2代表H；
R3代表H。
2.根据权利要求1的化合物或其药学上可接受的盐，其特征在于，R1代表
3.权利要求1的化合物或其药学上可接受的盐，其特征在于，通式(I)的化合物选自以下任意一种：
4.根据权利要求1～3中任一项的化合物或其药学上可接受的盐，其中药学上可接受的盐为权利要求1～3中任一项的化合物与下列酸形成的酸加成盐：氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
5.一种药物组合物，其特征在于，包含权利要求1～3中任一项的化合物或其药学上可接受的盐及药学上可接受的载体。
6.权利要求1～3中任一项的化合物或其药学上可接受的盐在制备BTK和JAK3双靶点抑制剂药物中的用途。
7.权利要求6的用途，所述的BTK和JAK3双靶点抑制剂是治疗类风湿性关节炎或B细胞淋巴瘤的药物。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110357313.2A CN115160319B (zh) | 2021-04-01 | 2021-04-01 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
| JP2023534994A JP2023552476A (ja) | 2021-04-01 | 2022-03-24 | １，３－ベンゾジオキソール構造を有する化合物及びその調製方法並びに用途 |
| EP22778714.0A EP4317162A1 (en) | 2021-04-01 | 2022-03-24 | 1,3-benzodioxolane-containing compound, and preparation method therefor and use thereof |
| US18/257,027 US20240059694A1 (en) | 2021-04-01 | 2022-03-24 | Compound containing 1,3-benzodioxol structure and preparation method and use thereof |
| PCT/CN2022/082684 WO2022206531A1 (zh) | 2021-04-01 | 2022-03-24 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110357313.2A CN115160319B (zh) | 2021-04-01 | 2021-04-01 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115160319A CN115160319A (zh) | 2022-10-11 |
| CN115160319B true CN115160319B (zh) | 2023-12-26 |
Family
ID=83457975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110357313.2A Active CN115160319B (zh) | 2021-04-01 | 2021-04-01 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240059694A1 (zh) |
| EP (1) | EP4317162A1 (zh) |
| JP (1) | JP2023552476A (zh) |
| CN (1) | CN115160319B (zh) |
| WO (1) | WO2022206531A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020231990A1 (en) * | 2019-05-13 | 2020-11-19 | Relay Therapeutics, Inc. | Fgfr inhibitors and methods of use thereof |
-
2021
- 2021-04-01 CN CN202110357313.2A patent/CN115160319B/zh active Active
-
2022
- 2022-03-24 WO PCT/CN2022/082684 patent/WO2022206531A1/zh active Application Filing
- 2022-03-24 US US18/257,027 patent/US20240059694A1/en active Pending
- 2022-03-24 JP JP2023534994A patent/JP2023552476A/ja active Pending
- 2022-03-24 EP EP22778714.0A patent/EP4317162A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020231990A1 (en) * | 2019-05-13 | 2020-11-19 | Relay Therapeutics, Inc. | Fgfr inhibitors and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022206531A1 (zh) | 2022-10-06 |
| JP2023552476A (ja) | 2023-12-15 |
| US20240059694A1 (en) | 2024-02-22 |
| EP4317162A1 (en) | 2024-02-07 |
| CN115160319A (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3423451B1 (en) | Inhibitors of wdr5 protein-protein binding | |
| EP3762380B1 (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| US6271251B1 (en) | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | |
| EP2961745B1 (en) | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors | |
| US11530183B2 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| KR20180022818A (ko) | 환화 술파모일아릴아미드 유도체 및 b형 간염 치료용 약제로서의 이의 용도 | |
| CN101094830A (zh) | 用作cxcr2抑制剂、治疗炎症的稠合双环甲酰胺衍生物 | |
| EP1786773A1 (en) | Isoindolin-1-one derivatives | |
| WO2002100845A1 (en) | Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | |
| WO2006088246A1 (ja) | Ｇｐｒ３４受容体機能調節剤 | |
| CN102702193A (zh) | 抗病毒化合物 | |
| US20100286152A1 (en) | N-phenyl hydrazides as modulators of the ghrelin receptor | |
| KR20170140370A (ko) | Jak 억제제 | |
| US11186544B2 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| KR20180006450A (ko) | 우레아 유도체 또는 그의 약리학상 허용되는 염 | |
| WO2004020414A1 (en) | Oxytocin inhibitors | |
| CN103874697A (zh) | 二苯并氧杂*衍生物 | |
| CN115160319B (zh) | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 | |
| JPS6045878B2 (ja) | Ｎ，ｎ’−二置換環状ジアミン及び精神病治療用薬剤 | |
| EP3986903B1 (en) | Biaryl dialkyl phosphine oxide fpr2 agonists | |
| JP2023527055A (ja) | がんの治療に使用するためのｌｉｍｋ及び／又はｒｏｃｋキナーゼ阻害剤としての４－（７ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－３，６－ジヒドロピリジン－１－（２ｈ）－カルボキサミド誘導体 | |
| CN101679191A (zh) | 二杂芳基环己烷衍生物、其制备方法、用途及含有它们的药用组合物 | |
| CN118005638A (zh) | 含吡唑并[3,4-d]嘧啶结构的化合物及其制备方法与用途 | |
| EP1633725A1 (en) | Hepatitis c virus inhibitors | |
| US7507726B2 (en) | Peptide deformylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |